Q2--12-310001789972falseYesYesFebruary 01, 2018June 30, 20240001789972us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972cgem:PearlTaihoPharmaMember2023-01-012023-06-300001789972us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100017899722022-01-012022-06-300001789972us-gaap:NoncontrollingInterestMember2023-06-300001789972cgem:CullinanMICACorpMemberus-gaap:SeriesAPreferredStockMember2023-01-012023-06-300001789972us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001789972us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:AdditionalPaidInCapitalMember2021-12-310001789972us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001789972cgem:CullinanPearlCorpMembercgem:HypotheticalLiquidationAtBookValueMember2022-04-012022-06-300001789972us-gaap:AdditionalPaidInCapitalMember2022-12-310001789972us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:RetainedEarningsMember2023-06-300001789972us-gaap:RetainedEarningsMember2021-12-3100017899722023-06-300001789972us-gaap:CommonStockMember2022-03-310001789972us-gaap:PreferredStockMember2022-01-012022-06-300001789972cgem:MassachusettsInstituteOfTechnologyMember2023-01-012023-06-300001789972us-gaap:CommonStockMember2023-06-3000017899722023-07-310001789972cgem:HypotheticalLiquidationAtBookValueMembercgem:CullinanMICACorpMember2023-01-012023-06-300001789972us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-06-300001789972cgem:HypotheticalLiquidationAtBookValueMembercgem:CullinanMICACorpMember2022-01-012022-06-300001789972us-gaap:RetainedEarningsMember2022-04-012022-06-300001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972cgem:MayThirtyOneTwoThousendThirtyThreeMember2023-06-300001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001789972us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:CommonStockMember2022-01-012022-03-3100017899722022-06-300001789972us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001789972cgem:CullinanAmberCorpMember2022-04-012022-06-300001789972us-gaap:RetainedEarningsMember2023-01-012023-03-310001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001789972us-gaap:PreferredStockMember2023-03-310001789972us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972cgem:LongTermInvestmentMemberus-gaap:CorporateNoteSecuritiesMember2022-12-310001789972cgem:CullinanAmberCorpMember2023-01-012023-06-300001789972us-gaap:PreferredStockMember2023-06-3000017899722022-04-012022-06-300001789972cgem:MassachusettsInstituteOfTechnologyMember2022-01-012022-06-300001789972us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001789972us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001789972us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-3000017899722017-12-012017-12-310001789972cgem:LongTermInvestmentMember2022-12-310001789972us-gaap:RetainedEarningsMember2022-01-012022-03-310001789972us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001789972us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001789972cgem:BiotechnologyValueFundLPExchangeAgreementMember2023-01-310001789972cgem:MassachusettsInstituteOfTechnologyMember2022-04-012022-06-300001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001789972cgem:PearlTaihoPharmaMember2023-06-300001789972cgem:PearlTaihoPharmaMember2023-04-012023-06-300001789972us-gaap:NoncontrollingInterestMember2023-01-012023-03-3100017899722023-04-012023-06-300001789972us-gaap:NoncontrollingInterestMember2021-12-310001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:RetainedEarningsMember2022-12-310001789972cgem:ShortTermInvestmentMember2023-06-300001789972us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:NoncontrollingInterestMember2023-03-310001789972us-gaap:PreferredStockMember2023-01-012023-03-310001789972us-gaap:RestrictedStockMember2023-01-012023-06-300001789972cgem:PearlTaihoPharmaMember2022-04-012022-06-300001789972cgem:ShortTermInvestmentMemberus-gaap:CorporateNoteSecuritiesMember2023-06-300001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001789972us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:NoncontrollingInterestMember2022-12-310001789972us-gaap:RetainedEarningsMember2023-03-310001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMembercgem:ShortTermInvestmentMember2022-12-310001789972cgem:ShortTermInvestmentMemberus-gaap:CorporateNoteSecuritiesMember2022-12-310001789972cgem:MayThirtyOneTwoThousendThirtyThreeMembercgem:AtTheMarketEquityOfferingProgramMember2023-04-012023-06-300001789972us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001789972us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:IndemnificationGuaranteeMember2022-12-3100017899722023-01-012023-03-310001789972us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:CommonStockMember2021-12-310001789972us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972cgem:CullinanAmberCorpMemberus-gaap:SeriesAPreferredStockMember2023-01-012023-06-300001789972cgem:CullinanAmberCorpMember2023-04-012023-06-300001789972us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001789972us-gaap:CommonStockMember2022-04-012022-06-3000017899722023-03-310001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMembercgem:ShortTermInvestmentMember2023-06-300001789972us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972cgem:LongTermInvestmentMemberus-gaap:CorporateNoteSecuritiesMember2023-06-300001789972us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-3000017899722022-01-012022-03-3100017899722023-01-012023-06-300001789972us-gaap:AssetBackedSecuritiesMembercgem:ShortTermInvestmentMember2022-12-310001789972us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001789972us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001789972us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2022-12-310001789972cgem:PearlTaihoPharmaMember2022-06-012022-06-300001789972us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972cgem:CullinanAmberCorpMember2022-01-012022-06-300001789972us-gaap:CommercialPaperMembercgem:ShortTermInvestmentMember2022-12-310001789972us-gaap:CommonStockMember2022-12-310001789972us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:AdditionalPaidInCapitalMember2022-06-300001789972us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972cgem:PearlTaihoPharmaMember2022-01-012022-06-300001789972us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:RetainedEarningsMember2022-06-300001789972us-gaap:CommonStockMember2023-04-012023-06-300001789972us-gaap:RestrictedStockMember2022-01-012022-06-300001789972cgem:HarbourBiomedUsIncMembersrt:MaximumMembercgem:HarbourLicenseAgreementMembercgem:SalesBasedMember2023-01-012023-06-300001789972us-gaap:IndemnificationGuaranteeMember2023-06-300001789972us-gaap:CommonStockMember2023-03-3100017899722022-03-310001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001789972cgem:HarbourBiomedUsIncMembercgem:HarbourLicenseAgreementMember2023-01-012023-06-300001789972cgem:LongTermInvestmentMember2023-06-300001789972us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001789972us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:AssetBackedSecuritiesMembercgem:ShortTermInvestmentMember2023-06-300001789972us-gaap:CommonStockMember2022-06-300001789972us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001789972us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:NoncontrollingInterestMember2022-03-3100017899722021-12-310001789972country:MA2017-12-012017-12-310001789972us-gaap:PreferredStockMember2023-01-012023-06-300001789972cgem:AdimabMember2022-01-012022-06-300001789972cgem:ShortTermInvestmentMember2022-12-310001789972us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001789972us-gaap:CommonStockMember2023-01-012023-03-310001789972cgem:HypotheticalLiquidationAtBookValueMembercgem:CullinanMICACorpMember2022-04-012022-06-300001789972cgem:MayThirtyOneTwoThousendThirtyThreeMembercgem:AtTheMarketEquityOfferingProgramMember2023-06-300001789972us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000017899722022-12-310001789972us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:RetainedEarningsMember2022-03-310001789972us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001789972cgem:CullinanPearlCorpMembercgem:HypotheticalLiquidationAtBookValueMember2022-01-012022-06-300001789972us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001789972us-gaap:RetainedEarningsMember2023-04-012023-06-300001789972country:MA2022-08-012022-08-310001789972cgem:HarbourLicenseAgreementMember2023-01-012023-06-300001789972us-gaap:AdditionalPaidInCapitalMember2023-06-300001789972us-gaap:AdditionalPaidInCapitalMember2022-03-310001789972cgem:AchievementBasedMembercgem:HarbourBiomedUsIncMembersrt:MaximumMembercgem:HarbourLicenseAgreementMember2023-01-012023-06-300001789972us-gaap:FairValueMeasurementsRecurringMember2022-12-310001789972cgem:HypotheticalLiquidationAtBookValueMembercgem:CullinanMICACorpMember2023-04-012023-06-300001789972cgem:CullinanFlorentineCorpMemberus-gaap:SeriesAPreferredStockMember2023-01-012023-06-300001789972us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001789972us-gaap:NoncontrollingInterestMember2022-06-300001789972us-gaap:AdditionalPaidInCapitalMember2023-03-31xbrli:pureutr:sqftxbrli:sharescgem:Segmentiso4217:USD
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2023
OR
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
Commission File Number: 001-39856
CULLINAN ONCOLOGY, INC.
(Exact name of Registrant as specified in its Charter)
|
|
Delaware |
81-3879991 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
One Main Street Suite 1350 Cambridge, MA |
02142 |
(Address of principal executive offices) |
(Zip Code) |
(617) 410-4650
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
CGEM |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES ☒ NO ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒
The number of shares of the Registrant’s common stock outstanding as of July 31, 2023 was 42,734,644.
The number of shares of the Registrant’s non-voting preferred stock outstanding as of July 31, 2023 was 647,500. Each share of the preferred stock will be convertible into 10 shares of common stock at the option of the holder at any time, subject to certain limitations, including that the holder will be prohibited from converting preferred stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock more than 9.99% of the total common stock then issued and outstanding immediately following the conversion of such shares of preferred stock. Shares of preferred stock will generally have no voting rights, except as required by law and except that the consent of a majority of the holders of the outstanding preferred stock will be required to amend the terms of the preferred stock. In the event of the Registrant's liquidation, dissolution or winding up, holders of preferred stock will participate pari passu with any distribution of proceeds to holders of common stock. The preferred stock ranks (i) senior to any class or series of capital stock of the Registrant hereafter created specifically ranking by its terms junior to the preferred stock; (ii) on parity with the common stock and any class or series of capital stock of the Registrant created specifically ranking by its terms on parity with the preferred stock; and (iii) junior to any class or series of capital stock of the Registrant created specifically ranking by its terms senior to any preferred stock, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Registrant, whether voluntarily or involuntarily.
Table of Contents
i
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 10-K") and other filings with the Securities Exchange Commission (the “SEC”), including the following:
•the success, cost and timing of our clinical-stage product candidates;
•the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available;
•our ability to initiate, recruit, and enroll patients in and conduct our clinical trials at the pace that we project;
•our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, or warnings in the label of any of our product candidates, if approved;
•our ability to compete with companies currently marketing therapies or developing product candidates with targets or indications similar to our product candidates;
•our reliance on third parties to conduct our clinical trials and to manufacture drug substance and drug product for use in our clinical trials;
•the size and growth potential of the markets for oncology therapies and any of our current product candidates or other product candidates we may identify and pursue, and our ability to serve those markets;
•our ability to identify and advance through clinical development any additional product candidates;
•the commercialization of our current product candidates and any other product candidates we may identify and pursue, if approved, including our ability to successfully build a specialty sales force and commercial infrastructure to market our current product candidates and any other product candidates we may identify and pursue;
•our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates;
•our ability to retain and recruit key personnel;
•our ability to obtain and maintain adequate intellectual property rights;
•our expectations regarding government and third-party payor coverage and reimbursement;
•our estimates of our expenses, ongoing losses, capital requirements, and our needs for or ability to obtain additional financing;
•the milestone payments that we may receive from Taiho Pharmaceutical Co., Ltd.;
•the anticipated development and commercialization of zipalertinib;
•potential investments in our pipeline and the potential for such product candidates;
•the potential benefits of strategic collaboration agreements, our ability to enter into additional strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory, and commercialization expertise;
•our financial performance; and
ii
•developments and projections relating to our competitors or our industry.
These factors are discussed more fully in our 2022 10-K and elsewhere in this Quarterly Report on Form 10-Q and other reports we file with the SEC. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and investors should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make or collaborations or strategic partnerships we may enter into.
You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This Quarterly Report on Form 10-Q also contains estimates, projections, and other information concerning our industry, our business, and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research, as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” in our 2022 10-K and elsewhere in this Quarterly Report on Form 10-Q.
iii
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
CULLINAN ONCOLOGY, INC.
Consolidated Balance Sheets
(unaudited)
(in thousands, except share amounts)
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
141,834 |
|
|
$ |
156,152 |
|
Short-term investments |
|
|
349,964 |
|
|
|
311,140 |
|
Prepaid expenses and other current assets |
|
|
6,437 |
|
|
|
7,180 |
|
Total current assets |
|
|
498,235 |
|
|
|
474,472 |
|
Property and equipment, net |
|
|
1,158 |
|
|
|
1,174 |
|
Operating lease right-of-use assets |
|
|
3,501 |
|
|
|
4,130 |
|
Other assets |
|
|
459 |
|
|
|
459 |
|
Long-term investments |
|
|
18,631 |
|
|
|
80,882 |
|
Total assets |
|
$ |
521,984 |
|
|
$ |
561,117 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
2,493 |
|
|
$ |
2,660 |
|
Accrued expenses and other current liabilities |
|
|
15,531 |
|
|
|
14,135 |
|
Income tax payable |
|
|
— |
|
|
|
4,282 |
|
Operating lease liabilities, current |
|
|
1,652 |
|
|
|
1,421 |
|
Total current liabilities |
|
|
19,676 |
|
|
|
22,498 |
|
Long-term liabilities: |
|
|
|
|
|
|
Operating lease liabilities, net of current portion |
|
|
2,734 |
|
|
|
3,590 |
|
Total liabilities |
|
|
22,410 |
|
|
|
26,088 |
|
Commitments and contingencies (Note 11) |
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 647,500 and no shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively. |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value, 150,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 42,735,304 and 45,796,449 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively |
|
|
4 |
|
|
|
5 |
|
Additional paid-in capital |
|
|
639,066 |
|
|
|
585,320 |
|
Accumulated other comprehensive loss |
|
|
(1,625 |
) |
|
|
(2,601 |
) |
Accumulated deficit |
|
|
(137,871 |
) |
|
|
(47,695 |
) |
Total Cullinan stockholders' equity |
|
|
499,574 |
|
|
|
535,029 |
|
Noncontrolling interests |
|
|
— |
|
|
|
— |
|
Total stockholders' equity |
|
|
499,574 |
|
|
|
535,029 |
|
Total liabilities and stockholders' equity |
|
$ |
521,984 |
|
|
$ |
561,117 |
|
See accompanying notes to the unaudited consolidated financial statements.
1
CULLINAN ONCOLOGY, INC.
Consolidated Statements of Operations and Comprehensive INCOME (LOSS)
(unaudited)
(in thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
27,391 |
|
|
$ |
26,411 |
|
|
$ |
79,487 |
|
|
$ |
50,947 |
|
General and administrative |
|
|
10,214 |
|
|
|
10,695 |
|
|
|
20,874 |
|
|
|
18,816 |
|
Total operating expenses |
|
|
37,605 |
|
|
|
37,106 |
|
|
|
100,361 |
|
|
|
69,763 |
|
Gain on sale of Cullinan Pearl |
|
|
— |
|
|
|
276,785 |
|
|
|
— |
|
|
|
276,785 |
|
Income (loss) from operations |
|
|
(37,605 |
) |
|
|
239,679 |
|
|
|
(100,361 |
) |
|
|
207,022 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
5,322 |
|
|
|
697 |
|
|
|
9,830 |
|
|
|
894 |
|
Other income (expense), net |
|
|
69 |
|
|
|
(241 |
) |
|
|
176 |
|
|
|
(241 |
) |
Net income (loss) before income taxes |
|
|
(32,214 |
) |
|
|
240,135 |
|
|
|
(90,355 |
) |
|
|
207,675 |
|
Income tax expense |
|
|
— |
|
|
|
66,070 |
|
|
|
— |
|
|
|
46,502 |
|
Net income (loss) |
|
|
(32,214 |
) |
|
|
174,065 |
|
|
|
(90,355 |
) |
|
|
161,173 |
|
Net loss attributable to noncontrolling interests |
|
|
— |
|
|
|
(833 |
) |
|
|
(179 |
) |
|
|
(1,627 |
) |
Net income (loss) attributable to common stockholders of Cullinan |
|
$ |
(32,214 |
) |
|
$ |
174,898 |
|
|
$ |
(90,176 |
) |
|
$ |
162,800 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
(32,214 |
) |
|
$ |
174,065 |
|
|
$ |
(90,355 |
) |
|
$ |
161,173 |
|
Unrealized gain (loss) on investments |
|
|
(383 |
) |
|
|
(499 |
) |
|
|
976 |
|
|
|
(2,795 |
) |
Comprehensive income (loss) |
|
|
(32,597 |
) |
|
|
173,566 |
|
|
|
(89,379 |
) |
|
|
158,378 |
|
Comprehensive loss attributable to noncontrolling interests |
|
|
— |
|
|
|
(833 |
) |
|
|
(179 |
) |
|
|
(1,627 |
) |
Comprehensive income (loss) attributable to Cullinan |
|
$ |
(32,597 |
) |
|
$ |
174,399 |
|
|
$ |
(89,200 |
) |
|
$ |
160,005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.82 |
) |
|
$ |
3.90 |
|
|
$ |
(2.24 |
) |
|
$ |
3.65 |
|
Diluted |
|
$ |
(0.82 |
) |
|
$ |
3.77 |
|
|
$ |
(2.24 |
) |
|
$ |
3.51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used in computing net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
39,952 |
|
|
|
44,873 |
|
|
|
40,315 |
|
|
|
44,654 |
|
Diluted |
|
|
39,952 |
|
|
|
46,381 |
|
|
|
40,315 |
|
|
|
46,389 |
|
See accompanying notes to the unaudited consolidated financial statements.
2
CULLINAN ONCOLOGY, INC.
Consolidated Statements of STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands, except share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Accumulated Other Comprehensive |
|
|
Accumulated |
|
|
Noncontrolling Interest in |
|
|
Total Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Subsidiaries |
|
|
Equity |
|
Balances at December 31, 2022 |
|
|
— |
|
|
$ |
— |
|
|
|
45,796,449 |
|
|
$ |
5 |
|
|
$ |
585,320 |
|
|
$ |
(2,601 |
) |
|
$ |
(47,695 |
) |
|
$ |
— |
|
|
$ |
535,029 |
|
Contributions from noncontrolling interests |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
179 |
|
|
|
179 |
|
Issuance of preferred stock in exchange for common stock |
|
|
647,500 |
|
|
|
— |
|
|
|
(6,475,000 |
) |
|
|
(1 |
) |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net issuance of common stock under equity-based compensation plans |
|
|
— |
|
|
|
— |
|
|
|
22,152 |
|
|
|
— |
|
|
|
(36 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(36 |
) |
Equity-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,259 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,259 |
|
Unrealized gain on investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,359 |
|
|
|
— |
|
|
|
— |
|
|
|
1,359 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(57,962 |
) |
|
|
(179 |
) |
|
|
(58,141 |
) |
Balances at March 31, 2023 |
|
|
647,500 |
|
|
|
— |
|
|
|
39,343,601 |
|
|
|
4 |
|
|
|
592,544 |
|
|
|
(1,242 |
) |
|
|
(105,657 |
) |
|
|
— |
|
|
|
485,649 |
|
Issuance of common stock |
|
|
— |
|
|
|
— |
|
|
|
3,310,000 |
|
|
|
— |
|
|
|
38,388 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
38,388 |
|
Net issuance of common stock under equity-based compensation plans |
|
|
— |
|
|
|
— |
|
|
|
81,703 |
|
|
|
— |
|
|
|
214 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
214 |
|
Equity-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,920 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,920 |
|
Unrealized loss on investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(383 |
) |
|
|
— |
|
|
|
— |
|
|
|
(383 |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(32,214 |
) |
|
|
— |
|
|
|
(32,214 |
) |
Balances at June 30, 2023 |
|
|
647,500 |
|
|
$ |
— |
|
|
|
42,735,304 |
|
|
$ |
4 |
|
|
$ |
639,066 |
|
|
$ |
(1,625 |
) |
|
$ |
(137,871 |
) |
|
$ |
— |
|
|
$ |
499,574 |
|
3
CULLINAN ONCOLOGY, INC.
Consolidated Statements of STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands, except share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Accumulated Other Comprehensive |
|
|
Accumulated |
|
|
Noncontrolling Interest in |
|
|
Total Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Subsidiaries |
|
|
Equity |
|
Balances at December 31, 2021 |
|
|
— |
|
|
$ |
— |
|
|
|
44,292,102 |
|
|
$ |
4 |
|
|
$ |
584,714 |
|
|
$ |
(838 |
) |
|
$ |
(158,909 |
) |
|
$ |
403 |
|
|
$ |
425,374 |
|
Contributions from noncontrolling interests |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,153 |
|
|
|
1,153 |
|
Net issuance of common stock under equity-based compensation plans |
|
|
— |
|
|
|
— |
|
|
|
367,924 |
|
|
|
— |
|
|
|
1,566 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,566 |
|
Equity-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,559 |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
|
|
6,565 |
|
Unrealized loss on investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,296 |
) |
|
|
— |
|
|
|
— |
|
|
|
(2,296 |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(12,098 |
) |
|
|
(794 |
) |
|
|
(12,892 |
) |
Balances at March 31, 2022 |
|
|
— |
|
|
|
— |
|
|
|
44,660,026 |
|
|
|
4 |
|
|
|
592,839 |
|
|
|
(3,134 |
) |
|
|
(171,007 |
) |
|
|
768 |
|
|
|
419,470 |
|
Contributions from noncontrolling interests |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
139 |
|
|
|
139 |
|
Net issuance of common stock under equity-based compensation plans |
|
|
— |
|
|
|
— |
|
|
|
736,372 |
|
|
|
1 |
|
|
|
2,834 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,835 |
|
Equity-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,602 |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
|
|
8,608 |
|
Unrealized loss on investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(499 |
) |
|
|
— |
|
|
|
— |
|
|
|
(499 |
) |
Net income (loss) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
174,898 |
|
|
|
(833 |
) |
|
|
174,065 |
|
Balances at June 30, 2022 |
|
|
— |
|
|
$ |
— |
|
|
|
45,396,398 |
|
|
$ |
5 |
|
|
$ |
604,275 |
|
|
$ |
(3,633 |
) |
|
$ |
3,891 |
|
|
$ |
80 |
|
|
$ |
604,618 |
|
See accompanying notes to the unaudited consolidated financial statements.
4
CULLINAN ONCOLOGY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
Operating activities: |
|
|
|
|
|
|
Net income (loss) |
|
$ |
(90,355 |
) |
|
$ |
161,173 |
|
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
|
|
|
|
|
|
Equity-based compensation expense |
|
|
15,179 |
|
|
|
15,173 |
|
Amortization (accretion) on marketable securities |
|
|
(3,516 |
) |
|
|
1,737 |
|
Depreciation and amortization |
|
|
153 |
|
|
|
25 |
|
Non-cash contributions from noncontrolling interests |
|
|
4 |
|
|
|
139 |
|
Gain on sale of Cullinan Pearl |
|
|
— |
|
|
|
(276,785 |
) |
Realized loss on marketable securities |
|
|
— |
|
|
|
109 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
1,161 |
|
|
|
(1,050 |
) |
Accounts payable |
|
|
(169 |
) |
|
|
(70 |
) |
Accrued expenses and other current liabilities |
|
|
(178 |
) |
|
|
5,719 |
|
Income tax payable |
|
|
(4,282 |
) |
|
|
46,502 |
|
Net cash used in operating activities |
|
|
(82,003 |
) |
|
|
(47,328 |
) |
Investing activities: |
|
|
|
|
|
|
Proceeds from sales and maturities of marketable securities |
|
|
198,094 |
|
|
|
158,933 |
|
Purchase of marketable securities |
|
|
(170,592 |
) |
|
|
(93,370 |
) |
Purchase of property and equipment |
|
|
(208 |
) |
|
|
— |
|
Proceeds from sale of Cullinan Pearl, net of escrow of $5,000 and cash transferred with sale of $2,898 |
|
|
— |
|
|
|
270,000 |
|
Net cash provided by investing activities |
|
|
27,294 |
|
|
|
335,563 |
|
Financing activities: |
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
38,388 |
|
|
|
— |
|
Proceeds from issuance of convertible notes |
|
|
1,825 |
|
|
|
2,200 |
|
Proceeds from net issuance of common stock under equity-based compensation plans |
|
|
178 |
|
|
|
4,401 |
|
Repayment of convertible note |
|
|
— |
|
|
|
(2,200 |
) |
Contributions from noncontrolling interests |
|
|
— |
|
|
|
1,153 |
|
Net cash provided by financing activities |
|
|
40,391 |
|
|
|
5,554 |
|
Net increase (decrease) in cash and cash equivalents |
|
|
(14,318 |
) |
|
|
293,789 |
|
Cash and cash equivalents at beginning of period |
|
|
156,152 |
|
|
|
59,774 |
|
Cash and cash equivalents at end of period |
|
$ |
141,834 |
|
|
$ |
353,563 |
|
SUPPLEMENTAL NONCASH DISCLOSURE |
|
|
|
|
|
|
Non-cash investing and financing activities and supplemental cash flow information |
|
|
|
|
|
|
Conversion of convertible note into noncontrolling interest |
|
$ |
175 |
|
|
$ |
— |
|
Cash paid for income taxes |
|
$ |
4,708 |
|
|
$ |
— |
|
See accompanying notes to the unaudited consolidated financial statements.
5
CULLINAN ONCOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(1)Nature of Business and Basis of Presentation
Organization
Cullinan Oncology, Inc., together with its consolidated subsidiaries ("Cullinan" or the "Company"), is a clinical-stage biopharmaceutical company focused on modality-agnostic targeted oncology that was incorporated in September 2016 and has a principal place of business in Cambridge, Massachusetts.
Liquidity
The Company has incurred significant operating losses, with the exception of 2022, and negative cash flows from operations since its inception and expects to continue to generate operating losses for the foreseeable future. Cullinan’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company’s product candidates. Cullinan is subject to a number of risks including, but not limited to, the need to obtain adequate additional funding for the ongoing and planned clinical development of its product candidates. Due to the numerous risks and uncertainties associated with pharmaceutical products and development, the Company is unable to accurately predict the timing or amount of funds required to complete development of its product candidates, and costs could exceed Cullinan’s expectations for a number of reasons, including reasons beyond the Company’s control.
Since inception, Cullinan has funded its operations primarily through the sale of equity securities and from licensing or selling the rights to its product candidates. The Company expects that its cash, cash equivalents and short-term investments of $491.8 million and long-term investments and interest receivable of $20.3 million as of June 30, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these unaudited consolidated financial statements. Interest receivable is included in prepaid expenses and other current assets on the consolidated balance sheets and represents accrued and unpaid interest on Cullinan's marketable securities.
(2)Summary of Significant Accounting Policies
Cullinan’s significant accounting policies have not changed materially from those disclosed in its annual audited consolidated financial statements and accompanying notes in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 10-K”), except for its accounting policy for equity-based compensation.
Basis of Presentation
The unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") and in accordance with applicable rules and regulations of the Securities Exchange Commission (the "SEC") for interim financial reporting and include the accounts of the Company and its consolidated subsidiaries. Cullinan considers consolidation of entities over which control is achieved by means other than voting rights. Intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment, which is developing early-stage cancer therapeutics. In the opinion of Cullinan’s management, the unaudited consolidated financial statements reflect all adjustments, which are normal and recurring in nature, and necessary for fair financial statement presentation. The preparation of these unaudited consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These unaudited consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual audited consolidated financial statements and accompanying notes included in the 2022 10-K.
Equity-Based Compensation
The fair value of equity-based awards is measured at the grant date and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized as they occur. Cullinan classifies equity-based compensation in its consolidated statements of operations and comprehensive income (loss) in the same manner in which the award recipient’s payroll costs or service payments are classified.
The fair value of service-based restricted stock units ("RSUs") is the closing market price of the Company's common stock on the grant date. Cullinan measures the fair value of market-based RSUs on the grant date using a Monte Carlo simulation model. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. Both the Monte Carlo simulation model and the Black-Scholes option pricing model require the input of objective and subjective assumptions. Certain assumptions used, including Cullinan's expected stock price volatility, involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, equity-based compensation expense could be materially different for future awards.
6
Prior to 2023, the expected volatility used in the Black-Scholes option pricing model for new options was based on historical volatilities of the stock prices of similar entities within the Company’s industry over a period of time commensurate with the expected term assumption. In 2023, Cullinan determined that a sufficient amount of historical information was available regarding the volatility of its stock price to begin using a blended rate that combines the Company's historical volatility with the historical volatilities of the stock prices of similar entities within the Company’s industry over a period of time commensurate with the expected term assumption.
Recently Issued Accounting Pronouncements
There are no recently issued accounting pronouncements that will have a material impact on Cullinan's consolidated financial statements.
(3)Sale of Cullinan Pearl
In June 2022, the Company sold its equity interest in its partially owned-subsidiary, Cullinan Pearl Corp. ("Cullinan Pearl"), which had worldwide rights to zipalertinib, excluding Japan, mainland China, Hong Kong, Macau, and Taiwan, to Taiho Pharmaceutical Co., Ltd ("Taiho") for an upfront payment of $275.0 million, with an increase to the purchase price in the amount of $2.9 million for cash held by Cullinan Pearl that was transferred with the sale. As of June 30, 2022, $5.0 million of the upfront payment was held in escrow. The escrow amount was released to Cullinan in the third quarter of 2022 once the Company and Taiho determined that no post-sale net working capital adjustment was necessary. Pursuant to the share purchase agreement with Taiho, Cullinan is also eligible to receive an additional $130.0 million tied to epidermal growth factor receptor exon20 non-small-cell lung cancer regulatory milestones.
The Company concluded the transaction was a sale of non-financial assets, which were comprised mainly of intellectual property rights and related intangible assets, and that it transferred control of the non-financial assets at the closing of the sale. Cullinan recognized a gain on sale of Cullinan Pearl of $276.8 million within income from operations in its consolidated statement of operations and other comprehensive income (loss) for the three and six months ended June 30, 2022. The table below sets forth the book value of the Cullinan Pearl assets and liabilities sold along with the calculation of the gain on sale based on the cash consideration received.
|
|
|
|
|
|
|
(in thousands) |
|
Book value of assets sold |
|
|
|
Cash |
|
$ |
2,898 |
|
Prepaid expenses and other current assets |
|
|
619 |
|
Amounts attributable to assets sold |
|
|
3,517 |
|
Book value of liabilities sold |
|
|
|
Accrued expenses and other current liabilities |
|
|
2,404 |
|
Amounts attributable to liabilities sold |
|
|
2,404 |
|
Total identifiable net assets sold |
|
|
1,113 |
|
Upfront consideration, inclusive of escrow of $5,000 and cash transferred of $2,898 |
|
|
277,898 |
|
Gain on sale of Cullinan Pearl |
|
$ |
276,785 |
|
During the six months ended June 30, 2022, Cullinan Pearl issued $2.2 million of convertible notes to an affiliate of Taiho. The Company repaid these convertible notes at the closing of the Cullinan Pearl sale.
Investments
Cullinan recognized its short-term and long-term investments by security type at June 30, 2023 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
202,320 |
|
|
$ |
— |
|
|
$ |
(1,113 |
) |
|
$ |
201,207 |
|
U.S. government notes |
|
|
74,708 |
|
|
|
3 |
|
|
|
(86 |
) |
|
|
74,625 |
|
Asset-backed securities |
|
|
74,434 |
|
|
|
— |
|
|
|
(302 |
) |
|
|
74,132 |
|
Total short-term investments |
|
|
351,462 |
|
|
|
3 |
|
|
|
(1,501 |
) |
|
|
349,964 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
18,758 |
|
|
|
— |
|
|
|
(127 |
) |
|
|
18,631 |
|
Total long-term investments |
|
|
18,758 |
|
|
|
— |
|
|
|
(127 |
) |
|
|
18,631 |
|
Total investments |
|
$ |
370,220 |
|
|
$ |
3 |
|
|
$ |
(1,628 |
) |
|
$ |
368,595 |
|
7
The Company recognized its short-term and long-term investments by security type at December 31, 2022 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
244,498 |
|
|
$ |
11 |
|
|
$ |
(1,743 |
) |
|
$ |
242,766 |
|
U.S. government notes |
|
|
34,029 |
|
|
|
— |
|
|
|
(290 |
) |
|
|
33,739 |
|
Commercial paper |
|
|
18,035 |
|
|
|
3 |
|
|
|
(13 |
) |
|
|
18,025 |
|
Asset-backed securities |
|
|
16,625 |
|
|
|
— |
|
|
|
(15 |
) |
|
|
16,610 |
|
Total short-term investments |
|
|
313,187 |
|
|
|
14 |
|
|
|
(2,061 |
) |
|
|
311,140 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
81,436 |
|
|
|
18 |
|
|
|
(572 |
) |
|
|
80,882 |
|
Total long-term investments |
|
|
81,436 |
|
|
|
18 |
|
|
|
(572 |
) |
|
|
80,882 |
|
Total investments |
|
$ |
394,623 |
|
|
$ |
32 |
|
|
$ |
(2,633 |
) |
|
$ |
392,022 |
|
Fair Value of Financial Instruments
The following table sets forth the fair value of Cullinan’s financial assets that were measured at fair value on a recurring basis as of June 30, 2023:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
— |
|
|
$ |
201,207 |
|
|
$ |
— |
|
|
$ |
201,207 |
|
U.S. government notes |
|
|
— |
|
|
|
74,625 |
|
|
|
— |
|
|
|
74,625 |
|
Asset-backed securities |
|
|
— |
|
|
|
74,132 |
|
|
|
— |
|
|
|
74,132 |
|
Total short-term investments |
|
|
— |
|
|
|
349,964 |
|
|
|
— |
|
|
|
349,964 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
— |
|
|
|
18,631 |
|
|
|
— |
|
|
|
18,631 |
|
Total long-term investments |
|
|
— |
|
|
|
18,631 |
|
|
|
— |
|
|
|
18,631 |
|
Total investments |
|
$ |
— |
|
|
$ |
368,595 |
|
|
$ |
— |
|
|
$ |
368,595 |
|
The following table sets forth the fair value of the Company’s financial assets that were measured at fair value on a recurring basis as of December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
— |
|
|
$ |
242,766 |
|
|
$ |
— |
|
|
$ |
242,766 |
|
U.S. government notes |
|
|
— |
|
|
|
33,739 |
|
|
|
— |
|
|
|
33,739 |
|
Commercial paper |
|
|
— |
|
|
|
18,025 |
|
|
|
— |
|
|
|
18,025 |
|
Asset-backed securities |
|
|
— |
|
|
|
16,610 |
|
|
|
— |
|
|
|
16,610 |
|
Total short-term investments |
|
|
— |
|
|
|
311,140 |
|
|
|
— |
|
|
|
311,140 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
— |
|
|
|
80,882 |
|
|
|
— |
|
|
|
80,882 |
|
Total long-term investments |
|
|
— |
|
|
|
80,882 |
|
|
|
— |
|
|
|
80,882 |
|
Total investments |
|
$ |
— |
|
|
$ |
392,022 |
|
|
$ |
— |
|
|
$ |
392,022 |
|
As of June 30, 2023 and December 31, 2022, the fair values of Cullinan's cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximated their carrying values due to the short-term nature of these instruments.
8
(5)Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following as of June 30, 2023 and December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
|
|
(in thousands) |
|
Accrued research and development expenses |
|
$ |
6,130 |
|
|
$ |
7,486 |
|
Due to Taiho under collaboration agreement, net |
|
|
3,378 |
|
|
|
— |
|
Accrued bonus |
|
|
3,108 |
|
|
|
4,516 |
|
Convertible note and accrued interest |
|
|
1,885 |
|
|
|
178 |
|
Other current liabilities |
|
|
1,030 |
|
|
|
1,955 |
|
Total accrued expenses and other current liabilities |
|
$ |
15,531 |
|
|
$ |
14,135 |
|
(6)License and Collaboration Agreements
Harbour License Agreement
In February 2023, the Company and Harbour BioMed US Inc. (“Harbour”) entered into a license and collaboration agreement (the “Harbour License Agreement”), pursuant to which Harbour granted to Cullinan an exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S.
Under the terms of the Harbour License Agreement, the Company paid Harbour an upfront license fee of $25.0 million at signing. Harbour will be eligible to receive up to $148.0 million in milestone payments based on the achievement of pre-specified development and regulatory milestones. Harbour is also eligible to receive up to an additional $415.0 million in sales-based milestones as well as tiered royalties up to the high teens on a licensed product-by-licensed product basis, as a percentage of U.S. commercial sales. In addition, under the Harbour License Agreement, Harbour granted Cullinan certain intellectual property rights to enable the Company to perform its obligations and exercise its rights under the Harbour License Agreement.
Unless earlier terminated, the Harbour License Agreement will continue in effect until the expiration of Cullinan’s royalty obligations. The Harbour License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party’s insolvency. The Company may terminate the Harbour License Agreement for convenience by providing 90 days written notice to Harbour. In the Harbour License Agreement, each party made customary representations and warranties and agreed to customary covenants, including, without limitation, with respect to indemnification, for transactions of this type.
Cullinan evaluated the Harbour License Agreement and determined that the exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S represented an asset acquisition of in-process research and development. The Company also determined that the asset had no alternative future use at the time of acquisition, and therefore the upfront license fee of $25.0 million was recorded within research and development expenses during the six months ended June 30, 2023.
Co-Development Agreement with Taiho
In June 2022, Cullinan and an affiliate of Taiho entered into a co-development agreement, pursuant to which the Company will collaborate to develop zipalertinib and will retain the option to co-commercialize zipalertinib in the U.S. Under the co-development agreement, development costs for zipalertinib shall be shared equally between Taiho and Cullinan with each party receiving 50% of any future pre-tax profits from potential U.S. sales of zipalertinib.
The Company concluded that the co-development agreement with Taiho is a collaborative arrangement because Cullinan is an active participant in the development of zipalertinib. Payments made to or received from Taiho for zipalertinib development activities after the execution of the co-development agreement are recorded within research and development expenses. For the three and six months ended June 30, 2023, the Company recorded research and development expense of $5.5 million and $10.2 million, respectively, related to its share of costs incurred by Taiho. Cullinan incurred $2.1 million and $3.1 million of costs that were reimbursable by Taiho during the three and six months ended June 30, 2023, respectively, which were recorded as a reduction to research and development expenses. The net amount of $3.4 million due to Taiho was recorded within accrued expenses and other current liabilities as of June 30, 2023.
Other License and Collaboration Expenses
During the six months ended June 30, 2023, Cullinan recorded $0.2 million in research and development expenses relating to the license agreement with the Massachusetts Institute of Technology (the "MIT License Agreement") for CLN-617. During the three and six months ended June 30, 2022, the Company recorded $0.2 million in research and development expenses relating to the MIT License Agreement.
During the six months ended June 30, 2022, Cullinan recorded $0.5 million in research and development expenses relating to a collaboration agreement with Adimab, LLC.
9
Common Stock
Each share of common stock entitles the holder to one vote and to receive dividends when and if declared by the board of directors of the Company. No dividends have been declared through June 30, 2023.
At-the-Market Equity Offering Program
In May 2023, Cullinan entered into an agreement with Cowen and Company, LLC (“Cowen”) to establish an at-the-market equity offering program (the “ATM") pursuant to which the Company may offer and sell up to $125.0 million of its common stock from time to time through Cowen, acting as its sales agent. In the three months ended June 30, 2023, the Company sold approximately 3.3 million shares under the ATM and received net proceeds of $38.4 million after deducting commissions. As of June 30, 2023, Cullinan had $85.6 million in shares of its common stock remaining under the ATM.
Preferred Stock
In January 2023, the Company entered into an exchange agreement with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (the “Stockholders”), pursuant to which the Stockholders exchanged 6.5 million shares of Cullinan’s common stock for 0.6 million shares of newly designated Series A convertible preferred stock, a “toothless” preferred stock, par value $0.0001 per share.
Each share of the preferred stock will be convertible into ten shares of common stock at the option of the holder at any time, subject to certain limitations, including that the holder will be prohibited from converting preferred stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock more than 9.99% of the total common stock then issued and outstanding immediately following the conversion of such shares of preferred stock. Holders of the preferred stock are permitted to increase this percentage to an amount not to exceed 19.99% upon 60 days notice.
Shares of preferred stock will generally have no voting rights, except as required by law and except that the consent of a majority of the holders of the outstanding preferred stock will be required to amend the terms of the preferred stock. In the event of the Company’s liquidation, dissolution or winding up, holders of preferred stock will participate pari passu with any distribution of proceeds to holders of common stock. Holders of preferred stock are entitled to receive when, as, and if dividends are declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of preferred stock are otherwise not entitled to dividends.
The preferred stock ranks (i) senior to any class or series of capital stock of Cullinan hereafter created specifically ranking by its terms junior to the preferred stock; (ii) on parity with the common stock and any class or series of capital stock of the Company created specifically ranking by its terms on parity with the preferred stock; and (iii) junior to any class or series of capital stock of Cullinan created specifically ranking by its terms senior to any preferred stock, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.
The Company evaluated the preferred stock for liability or equity classification. Cullinan determined that the preferred stock should be classified as permanent equity as it is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company.
Noncontrolling Interests in Subsidiaries
Certain subsidiaries issue common stock in connection with licensing agreements and to employees, directors and consultants pursuant to subsidiary equity incentive plans. The holders of subsidiary common stock are entitled to one vote per share. The holders of subsidiary common stock are entitled to receive dividends when and if declared by the subsidiaries’ board of directors and distributions in either case only after the payment of all preferential amounts required to be paid to the holders of shares of preferred stock of the respective subsidiary.
Cullinan Amber
As of June 30, 2023, the Company held common stock and Series A preferred stock that represented 94% of Cullinan Amber Corp.’s ("Cullinan Amber") outstanding equity. As of June 30, 2023, noncontrolling interests collectively held common stock that represented 6% of Cullinan Amber's outstanding equity.
In each of the three and six months ended June 30, 2023, no losses were attributed to the noncontrolling interests of Cullinan Amber. In each of the three and six months ended June 30, 2022, $0.1 million of losses were attributed to the noncontrolling interests of Cullinan Amber.
Cullinan Florentine
As of June 30, 2023, Cullinan held common stock, Series A preferred stock and Series B preferred stock that represented 96% of Cullinan Florentine Corp.'s ("Cullinan Florentine") outstanding equity. As of June 30, 2023, noncontrolling interests collectively held common stock that represented 4% of Cullinan Florentine's outstanding equity.
10
In each of the three and six months ended June 30, 2023 and 2022, no losses were attributed to the noncontrolling interests of Cullinan Florentine.
Cullinan MICA
As of June 30, 2023, Cullinan held common stock and Series A preferred stock that represented 96% of Cullinan MICA Corp.'s ("Cullinan MICA") outstanding equity. As of June 30, 2023, noncontrolling interests collectively held common stock and Series A preferred stock that represented 4% of Cullinan MICA's outstanding equity.
In the three and six months ended June 30, 2023, no losses and $0.2 million of losses, respectively, were attributed to the noncontrolling interests of Cullinan MICA. In the three and six months ended June 30, 2022, $0.7 million and $1.1 million of losses, respectively, were attributed to the noncontrolling interests of Cullinan MICA.
Cullinan Pearl
In June 2022, the Company sold its equity interest in its partially-owned subsidiary, Cullinan Pearl, to Taiho. Refer to Note 3 for additional details relating to the transaction.
In the three and six months ended June 30, 2022, no losses and $0.3 million of losses, respectively, were attributed to the noncontrolling interests of Cullinan Pearl.
(8)Equity-Based Compensation
Cullinan recorded equity-based compensation in the following expense categories in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Research and development |
|
$ |
3,249 |
|
|
$ |
4,379 |
|
|
$ |
6,303 |
|
|
$ |
7,039 |
|
General and administrative |
|
|
4,671 |
|
|
|
4,229 |
|
|
|
8,876 |
|
|
|
8,134 |
|
Total equity-based compensation |
|
$ |
7,920 |
|
|
$ |
8,608 |
|
|
$ |
15,179 |
|
|
$ |
15,173 |
|
Determining Fair Value of Options
The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the value of the underlying common stock at the grant date, expected term, expected volatility, risk-free interest rate and dividend yield. The fair value of each grant of options during the six months ended June 30, 2023 and 2022 were determined using the methods and assumptions discussed below:
•The expected term of options is determined using the “simplified” method, as prescribed in the SEC Staff Accounting Bulletin No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.
•The risk-free interest rate is based on implied yields available from U.S. Treasury securities with a remaining term equal to the expected term assumed at the grant date.
•Prior to 2023, the expected volatility used in the Black-Scholes option pricing model for new options was based on historical volatilities of the stock prices of similar entities within Cullinan’s industry over a period of time commensurate with the expected term assumption. In 2023, the Company determined that a sufficient amount of historical information was available regarding the volatility of its stock price to begin using a blended rate that combines its historical volatility with the historical volatilities of the stock prices of similar entities within Cullinan’s industry over a period of time commensurate with the expected term assumption.
•The estimated annual dividend yield was based on the Company’s expectation of not paying dividends on its common stock in the foreseeable future.
The grant date fair value was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted-average assumptions in the six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
2023 |
|
2022 |
Risk-free interest rate |
|
3.9% |
|
2.2% |
Expected term (in years) |
|
6.0 |
|
6.0 |
Expected volatility |
|
79.1% |
|
78.8% |
Expected dividend yield |
|
0.0% |
|
0.0% |
11
(9)Related Party Transactions
Royalty Transfer Agreements
Cullinan Amber, Cullinan Florentine and Cullinan MICA are each party to royalty transfer agreements with MPM Oncology Charitable Foundation, Inc. and UBS Optimus Foundation (together, the "Foundations"). Under each of these respective agreements, the Foundations are collectively entitled to receive a low single digit royalty percentage of all global net sales of any products developed by the applicable subsidiary, subject to limitations after patent expirations and on intellectual property developed after a change of control. Cullinan has deemed these royalty transfer agreements to be freestanding financial instruments that should be accounted for at fair value. The Company concluded that these instruments had no value at the inception of the agreements.
Cullinan has not had any applicable net sales from its products and as a result, has not paid or incurred any royalties under these agreements as of June 30, 2023. Given the early-stage nature of the underlying technologies and inherent technical, regulatory and competitive risks associated with achieving approval and commercialization, the Company ascribed no value to the royalty transfer agreements as of June 30, 2023 and December 31, 2022.
During each of the three and six months ended June 30, 2023, Cullinan did not record an income tax expense or benefit.
During the three and six months ended June 30, 2022, the Company recorded an income tax provision of $66.1 million and $46.5 million, respectively. The tax provision recorded for the period ended June 30, 2022 was driven by the expected tax from the gain on sale of Cullinan Pearl, partially offset by the release of valuation allowance for the expected utilization of certain historical tax attributes against the gain from the sale. Refer to Note 3 for additional details on the sale of Cullinan's equity interest in Cullinan Pearl.
The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of capitalized research and development costs, temporary differences on equity-based compensation, and net operating loss carryforwards. Cullinan has considered its history of cumulative net losses and its estimated future taxable income and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, Cullinan has maintained a full valuation allowance against its remaining net deferred tax assets as of June 30, 2023.
(11)Commitments and Contingencies
The Company enters into contracts in the normal course of business with contract research organizations, contract manufacturing organizations, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These agreements generally include cancellation clauses.
Indemnification Agreements
In the ordinary course of business, Cullinan may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require Cullinan, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in certain cases, unlimited. To date, Cullinan has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2023 and December 31, 2022.
Legal Proceedings
Cullinan is not currently party to or aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. Cullinan expenses as incurred the costs related to such legal proceedings.
The Company has an operating lease for approximately 8,000 square feet of office space in a multi-tenant building in Cambridge, Massachusetts, which commenced in February 2018 and goes through June 2024 (the "Suite 520 Lease"). In August 2022, Cullinan entered into an additional operating lease for approximately 14,000 square feet of office space in a multi-tenant building in Cambridge, Massachusetts through July 2026. Lease expense consisted of operating lease costs of $0.4 million and $0.9 million for the three and six months ended June 30, 2023, respectively. Lease expense consisted of operating lease costs of $0.1 million and $0.3 million for the three and six months ended June 30, 2022, respectively.
12
The following table summarizes supplemental cash flow information for the six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Cash paid for amounts included in measurement of lease liabilities: |
|
|
|
|
|
|
Operating cash flows from operating leases |
|
$ |
875 |
|
|
$ |
303 |
|
Right-of-use asset obtained in exchange for an operating lease liability |
|
$ |
— |
|
|
$ |
1,311 |
|
The following table summarizes the Company’s future minimum lease payments and reconciliation of lease liabilities as of June 30, 2023:
|
|
|
|
|
|
|
June 30, 2023 |
|
|
|
(in thousands) |
|
Remainder of 2023 |
|
$ |
1,006 |
|
2024 |
|
|
1,738 |
|
2025 |
|
|
1,461 |
|
2026 |
|
|
872 |
|
Total future minimum lease payments |
|
|
5,077 |
|
Less: imputed interest |
|
|
(691 |
) |
Total lease liabilities at present value |
|
$ |
4,386 |
|
The following table summarizes the weighted-average remaining lease term and discount rate as of June 30, 2023 and December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
Weighted-average remaining lease term (in years) |
|
|
2.8 |
|
|
|
3.2 |
|
Weighted-average discount rate |
|
|
10.8 |
% |
|
|
10.8 |
% |
As Cullinan’s operating leases did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available in determining the present value of lease payments. Cullinan’s incremental borrowing rate was based on the term of the lease, the economic environment and reflects the rate the Company would have had to pay to borrow on a secured basis.
Sublease Agreement
In September 2022, Cullinan entered into a sublease agreement through May 2024 for the Suite 520 Lease. For the three and six months ended June 30, 2023, the Company recorded sublease income of $0.1 million and $0.3 million, respectively, within other income (expense), net.
(13)Net Income (Loss) per Share
The following table sets forth the calculation of basic and diluted net income (loss) per share for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands, except per share data) |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders of Cullinan |
|
$ |
(32,214 |
) |
|
$ |
174,898 |
|
|
$ |
(90,176 |
) |
|
$ |
162,800 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common stock outstanding - basic |
|
|
39,952 |
|
|
|
44,873 |
|
|
|
40,315 |
|
|
|
44,654 |
|
Dilutive effect of common stock issuable from assumed exercise of equity awards |
|
|
— |
|
|
|
1,508 |
|
|
|
— |
|
|
|
1,735 |
|
Weighted-average common stock outstanding - diluted |
|
|
39,952 |
|
|
|
46,381 |
|
|
|
40,315 |
|
|
|
46,389 |
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.82 |
) |
|
$ |
3.90 |
|
|
$ |
(2.24 |
) |
|
$ |
3.65 |
|
Diluted |
|
$ |
(0.82 |
) |
|
$ |
3.77 |
|
|
$ |
(2.24 |
) |
|
$ |
3.51 |
|
13
Cullinan used the treasury stock and if-converted methods to determine the number of dilutive shares. The following table sets forth potential common shares that were excluded from the computation of diluted net income (loss) per share for the six months ended June 30, 2023 and 2022 because their effect would have been anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Stock options |
|
|
9,185 |
|
|
|
6,250 |
|
Preferred stock |
|
|
5,795 |
|
|
|
— |
|
Restricted stock awards and RSUs |
|
|
156 |
|
|
|
— |
|
Total |
|
|
15,136 |
|
|
|
6,250 |
|
14
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 10-K”), filed with the Securities and Exchange Commission (the “SEC”) on March 9, 2023. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results could differ materially from those discussed in these forward-looking statements. Please also refer to those factors described in “Part I, Item 1A. Risk Factors” of our 2022 10-K for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements.
Overview
We are a clinical-stage biopharmaceutical company focused on modality-agnostic targeted oncology therapies. Our strategy is to identify high-impact cancer targets and then select what we believe is the optimal therapeutic modality for those targets. We source innovation both internally and externally, focusing on product candidates with novel technology platforms or differentiated mechanisms. Before we advance a product candidate into clinical development, we evaluate its potential for anti-tumor activity as a single agent as well as its ability to generate an immune response or to inhibit oncogenic processes. Using this strategy, we have built a broad and deep pipeline of targeted oncology programs that includes six distinct product candidates, all of which are clinical-stage, as well as multiple research and discovery programs.
Zipalertinib (CLN-081/TAS6417), which we are co-developing with an affiliate of Taiho Pharmaceutical Co., Ltd ("Taiho"), is an orally-available small-molecule, irreversible epidermal growth factor receptor ("EGFR") inhibitor that is designed to selectively target cells expressing EGFR exon 20 ("EGFRex20") insertion mutations with relative sparing of cells expressing wild-type EGFR. The United States ("U.S.") Food and Drug Administration (the "FDA") has granted Breakthrough Therapy designation to zipalertinib. In collaboration with our partners at Taiho, we are evaluating zipalertinib in a pivotal Phase 2b trial in patients with EGFRex20 non-small-cell lung cancer ("NSCLC") who progressed after prior systemic therapy, and in a global Phase 3 trial in combination with chemotherapy as a potential first-line treatment for EGFRex20 NSCLC adult patients.
In addition to zipalertinib, our portfolio includes five other clinical-stage product candidates:
•CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by both cytotoxic innate and adaptive immune cells. CLN-619 has broad therapeutic potential and is being investigated as both monotherapy and in combination with checkpoint inhibitor therapy in an ongoing Phase 1 trial in patients with advanced solid tumors. We presented initial clinical data for CLN-619 monotherapy in patients with advanced solid tumors at the 2023 American Society of Clinical Oncology Annual Meeting in June 2023. Data demonstrated monotherapy anti-tumor activity of CLN-619 in heavily pre-treated patients with multiple tumor types with no dose limiting toxicities up to the highest dose tested. Best responses among 22 evaluable patients receiving doses greater than one milligram per kilogram included one confirmed complete response (parotid cancer), two confirmed partial responses (endometrial cancer), and seven patients with stable disease (cervical, ovarian, breast, and salivary gland cancers).
oBased on these initial clinical observations, we have initiated monotherapy expansion cohorts in endometrial and cervical cancers and are evaluating potential additional future expansion cohorts.
oWe intend to present initial data from the combination dose escalation arm of the study at a medical meeting in the future.
•CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody being investigated in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
oPreliminary safety data from an ongoing first-in-human study were published in abstract form as part of the 2023 European Hematology Association Congress.
oEnrollment continues in the ongoing Phase 1 multi-ascending dose study using subcutaneous administration.
•CLN-418 is a B7H4x4-1BB fully human bispecific immune activator designed to achieve conditional activation of 4-1BB by targeting B7H4, a tumor-associated antigen that is highly expressed across multiple cancers with minimal expression on normal tissues, and is being investigated in an ongoing Phase 1 trial in patients with advanced solid tumors with initial clinical data expected in 2024.
•CLN-978 is a CD19xCD3 T cell engager with extended serum half-life and robust potency against target cells expressing low levels of CD19. In January 2023, the FDA cleared our investigational new drug application (“IND") for CLN-978, which we are initially evaluating in a Phase 1 trial for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (“r/r B-NHL”). In August 2023, we dosed the first patient in our Phase 1 trial of CLN-978 in patients with r/r B-NHL.
15
•CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 ("IL-2") and interleukin-12 ("IL-12"), with tumor retention domains for the treatment of solid tumors. In March 2023, the FDA cleared our IND for CLN-617. We anticipate initiating a Phase 1 clinical study in the second half of 2023 evaluating CLN-617 for the treatment of advanced solid tumors.
In addition to the product candidates described above, we are actively developing several preclinical oncology programs, all in the discovery stage, including our collaboration with Icahn School of Medicine at Mount Sinai for the development of novel hematopoietic progenitor kinase 1 degraders.
We have the option to co-commercialize zipalertinib with Taiho in the United States. We hold worldwide development and commercialization rights to CLN-619, CLN-049, CLN-978 and CLN-617, and we hold U.S. development and commercialization rights to CLN-418. We hold intellectual property rights and exclusive options for worldwide intellectual property for our earlier-stage programs.
Since our inception in 2016, we have focused all of our efforts and financial resources on raising capital, organizing and staffing our company, identifying, acquiring or in-licensing and developing product and technology rights, establishing and protecting our intellectual property portfolio and developing and advancing our programs. We do not have any products approved for sale and have not generated any revenue from product sales.
We have funded our operations primarily through the sale of equity securities and from licensing or selling the rights to our product candidates. As of June 30, 2023, we have received net proceeds of $579.6 million from equity financings, $18.9 million in revenue from a previous license agreement, and cash proceeds of $275.0 million from the sale of our equity interest in Cullinan Pearl to Taiho in June 2022.
As of June 30, 2023, we had cash, cash equivalents and short-term investments of $491.8 million and long-term investments and interest receivable of $20.3 million. Interest receivable is included in prepaid expenses and other current assets on the consolidated balance sheets and represents accrued and unpaid interest on our marketable securities. We have incurred significant operating losses, with the exception of 2022, and have had negative cash flows from operations since our inception. As of June 30, 2023, we had an accumulated deficit of $137.9 million. We expect to continue to generate operating losses for the foreseeable future. Our future viability is dependent on the success of our research and development and our ability to access additional capital to fund our operations. There can be no assurance that our current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all.
We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the ability to obtain additional capital to fund operations. Our therapeutic programs will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require additional capital, adequate personnel and extensive compliance-reporting capabilities. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable.
Basis of Presentation and Consolidation
When we were a private company, we established or acquired partially-owned development subsidiaries to hold the intellectual property rights for several of our product candidates. As a publicly held company, we do not intend to create new development subsidiaries in the future. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations and comprehensive income (loss). The following table shows our ownership interest as of June 30, 2023 in our partially-owned subsidiaries:
|
|
|
|
|
Name |
|
Ownership as of June 30, 2023 |
|
Cullinan MICA Corp. |
|
|
96 |
% |
Cullinan Florentine Corp. |
|
|
96 |
% |
Cullinan Amber Corp. |
|
|
94 |
% |
Cullinan Pearl Corp. |
|
|
— |
|
Cullinan MICA
Cullinan MICA Corp. is our partially-owned operating subsidiary that owns intellectual property related to CLN-619, our MICA/B-targeted humanized IgG1 monoclonal antibody.
16
Cullinan Florentine
Cullinan Florentine Corp. is our partially-owned operating subsidiary that has exclusive worldwide rights to CLN-049, our bispecific antibody targeting FLT3 and CD3, pursuant to an exclusive license agreement with Deutsches Krebsforschungszentrum, Eberhard Karls University of Tübingen, Faculty of Medicine, and Universitätsmedizin Gesellschaft für Forschung und Entwicklung mbH, Tübingen.
Cullinan Amber
Cullinan Amber Corp. is our partially-owned operating subsidiary that has exclusive worldwide rights to CLN-617, our fusion protein combining two potent antitumor cytokines, IL-2 and IL-12, with tumor retention domains for the treatment of solid tumors, pursuant to a license agreement with the Massachusetts Institute of Technology ("MIT”). The license agreement with MIT provides exclusive worldwide rights to the patents related to technology that originated in the laboratory of Dr. Karl Dane Wittrup to develop novel multifunctional constructs for delivery of immunostimulatory agents such as cytokines that are retained in the tumor microenvironment.
Cullinan Pearl
We sold our equity interest in our partially-owned subsidiary, Cullinan Pearl Corp., to Taiho in June 2022, which provided Taiho with worldwide rights to zipalertinib outside of Japan, mainland China, Hong Kong, Macau, and Taiwan.
Components of Our Results of Operations
Revenue
We have not generated any revenue from the sale of products since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all.
Research and Development Expenses
Research and development expenses consist primarily of costs incurred in connection with the research and development of our wholly-owned and jointly-developed product candidates and programs. These expenses include:
•compensation costs for employees engaged in research and development functions;
•expenses incurred under agreements with organizations that support our drug discovery and development activities;
•expenses incurred in connection with the preclinical and clinical development of our product candidates and programs, including under agreements with contract research organizations ("CROs");
•costs related to contract manufacturing organizations, that are primarily engaged to provide drug substance, raw material and drug product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct our clinical trials, nonclinical studies and other scientific development services;
•the costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches;
•costs related to compliance with quality and regulatory requirements;
•payments made under third-party licensing agreements; and
•direct and allocated costs related to facilities, information technology, personnel and other overhead.
Following the sale of our equity interest in Cullinan Pearl in the second quarter of 2022, development costs and any future potential pre-tax profits from U.S. sales of zipalertinib are shared equally between us and Taiho.
General and Administrative Expenses
General and administrative expenses consist primarily of compensation costs for personnel in executive management, finance, legal, corporate and business development, and other administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; administrative travel expenses; marketing expenses; and other operating costs.
Gain on Sale of Cullinan Pearl
Gain on sale of Cullinan Pearl represents the excess of the consideration received over the carrying value of the non-financial assets sold. Refer to Note 3 of our notes to the consolidated financial statements in this Quarterly Report on Form 10-Q for additional details relating to the transaction.
17
Other Income
Other income consists primarily of interest income earned on our cash, cash equivalents, short-term investments and long-term investments.
Income Taxes
Income taxes consist primarily of federal and state income taxes.
Results of Operations
Comparison of the Three and Six Months Ended June 30, 2023 and 2022
The following table presents our results of operations for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
27,391 |
|
|
$ |
26,411 |
|
|
$ |
79,487 |
|
|
$ |
50,947 |
|
General and administrative |
|
|
10,214 |
|
|
|
10,695 |
|
|
|
20,874 |
|
|
|
18,816 |
|
Total operating expenses |
|
|
37,605 |
|
|
|
37,106 |
|
|
|
100,361 |
|
|
|
69,763 |
|
Gain on sale of Cullinan Pearl |
|
|
— |
|
|
|
276,785 |
|
|
|
— |
|
|
|
276,785 |
|
Income (loss) from operations |
|
|
(37,605 |
) |
|
|
239,679 |
|
|
|
(100,361 |
) |
|
|
207,022 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
5,322 |
|
|
|
697 |
|
|
|
9,830 |
|
|
|
894 |
|
Other income (expense), net |
|
|
69 |
|
|
|
(241 |
) |
|
|
176 |
|
|
|
(241 |
) |
Net income (loss) before income taxes |
|
|
(32,214 |
) |
|
|
240,135 |
|
|
|
(90,355 |
) |
|
|
207,675 |
|
Income tax expense |
|
|
— |
|
|
|
66,070 |
|
|
|
— |
|
|
|
46,502 |
|
Net income (loss) |
|
|
(32,214 |
) |
|
|
174,065 |
|
|
|
(90,355 |
) |
|
|
161,173 |
|
Net loss attributable to noncontrolling interests |
|
|
— |
|
|
|
(833 |
) |
|
|
(179 |
) |
|
|
(1,627 |
) |
Net income (loss) attributable to common stockholders of Cullinan |
|
$ |
(32,214 |
) |
|
$ |
174,898 |
|
|
$ |
(90,176 |
) |
|
$ |
162,800 |
|
Research and Development Expenses
The following table summarizes our research and development expenses for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Zipalertinib |
|
$ |
7,760 |
|
|
$ |
4,245 |
|
|
$ |
13,412 |
|
|
$ |
12,143 |
|
CLN-619 |
|
|
5,991 |
|
|
|
5,606 |
|
|
|
10,503 |
|
|
|
9,167 |
|
CLN-049 |
|
|
2,650 |
|
|
|
1,226 |
|
|
|
4,793 |
|
|
|
2,350 |
|
CLN-418 |
|
|
1,091 |
|
|
|
— |
|
|
|
27,970 |
|
|
|
— |
|
CLN-978 |
|
|
(182 |
) |
|
|
3,064 |
|
|
|
1,643 |
|
|
|
6,857 |
|
CLN-617 |
|
|
1,753 |
|
|
|
2,738 |
|
|
|
4,045 |
|
|
|
4,518 |
|
Clinical-stage product candidates |
|
|
19,063 |
|
|
|
16,879 |
|
|
|
62,366 |
|
|
|
35,035 |
|
Early-stage research |
|
|
1,024 |
|
|
|
2,247 |
|
|
|
2,551 |
|
|
|
4,108 |
|
Other personnel and unallocated |
|
|
4,055 |
|
|
|
2,906 |
|
|
|
8,267 |
|
|
|
4,764 |
|
Equity-based compensation |
|
|
3,249 |
|
|
|
4,379 |
|
|
|
6,303 |
|
|
|
7,040 |
|
Total research and development expenses |
|
$ |
27,391 |
|
|
$ |
26,411 |
|
|
$ |
79,487 |
|
|
$ |
50,947 |
|
The $1.0 million increase in research and development expenses in the three months ended June 30, 2023 compared to the same period in 2022 was primarily related to increased clinical costs ($7.6 million) and higher personnel costs due to increased headcount and expansion of operations to support our research and development activities ($2.4 million), partially offset by a decrease in chemistry, manufacturing and controls ("CMC") costs ($4.8 million), lower preclinical costs ($2.8 million) and lower equity-based compensation costs ($1.1 million).
The $28.5 million increase in research and development expenses in the six months ended June 30, 2023 compared to the same period in 2022 was primarily related to the upfront fee due upon in-licensing CLN-418 ($25.0 million), increased clinical costs ($11.8 million) and higher personnel costs due to increased headcount and expansion of operations to support our research and development activities ($4.9 million), partially offset by lower preclinical costs ($6.9 million), a decrease in chemistry, manufacturing and controls ("CMC") costs ($5.7 million), and lower equity-based compensation costs ($0.7 million).
18
General and Administrative Expenses
The decrease of $0.5 million in general and administrative expenses in the three months ended June 30, 2023 compared to the same period in 2022 was primarily due to one-time expenses related to the sale of Cullinan Pearl in 2022 that did not recur in 2023 ($1.7 million), partially offset by increases in equity-based compensation ($0.4 million) and other personnel costs ($0.3 million) relating to increased headcount.
The increase of $2.1 million in general and administrative expenses in the six months ended June 30, 2023 compared to the same period in 2022 was primarily due to increases in personnel costs ($1.4 million), legal and other professional fees ($1.3 million), equity-based compensation ($0.7 million), and occupancy and insurance costs to support our expanded operations ($0.6 million), partially offset by one-time expenses related to the sale of Cullinan Pearl in 2022 that did not recur in 2023 ($2.0 million).
Gain on Sale of Cullinan Pearl
Gain on sale of Cullinan Pearl represents the excess of the consideration received over the carrying value of the non-financial assets sold. Refer to Note 3 of our notes to the consolidated financial statements in this Quarterly Report on Form 10-Q for additional details relating to the transaction.
Other Income
The $4.9 million increase in other income in the three months ended June 30, 2023 compared to the same period in 2022 was primarily related to higher investment income.
The $9.4 million increase in other income in the six months ended June 30, 2023 compared to the same period in 2022 was primarily related to higher investment income.
Income Tax Expense (Benefit)
We did not record income tax expense or benefit for the three or six months ended June 30, 2023.
The income tax expense was $66.1 million and $46.5 million for the three and six months ended June 30, 2022, respectively. The net income tax expense of $46.5 million recognized for the six months ended June 30, 2022 represented the expected tax from the gain on sale of Cullinan Pearl, including the expected utilization of certain historical tax attributes.
Net Loss Attributable to Noncontrolling Interests
There was no net loss attributable to noncontrolling interests during the three months ended June 30, 2023. Net loss attributable to noncontrolling interests was $0.8 million during the three months ended June 30, 2022. Net loss attributable to noncontrolling interests was $0.2 million and $1.6 million during the six months ended June 30, 2023 and 2022, respectively.
Net loss attributable to noncontrolling interests is determined as the difference in the noncontrolling interest in the consolidated balance sheets between the start and end of each reporting period, after taking into account any capital transactions between our partially-owned subsidiaries and third parties. Refer to Note 7 of our notes to the consolidated financial statements included in this Quarterly Report on Form 10-Q for additional details of capital transactions between our partially-owned subsidiaries and third parties.
Liquidity and Capital Resources
Overview
We have a history of significant operating losses, with the exception of 2022, and have had negative cash flows from operations since our inception and expect to continue to generate operating losses for the foreseeable future. We have not yet commercialized any products, and we do not expect to generate revenue from sales of products for several years, if at all. To date, we have funded our operations primarily with proceeds from the sale of equity securities and from licensing or selling the rights to our product candidates. As of June 30, 2023, we had cash, cash equivalents and short-term investments of $491.8 million and long-term investments and interest receivable of $20.3 million.
Based on our current operational plans and assumptions, we expect that our current cash, cash equivalents, short-term investments, and long-term investments will be sufficient to fund operations through at least twelve months from the date of issuance of our consolidated financial statements. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We cannot guarantee that we will be able to raise additional capital on reasonable terms or at all.
In February 2023, we entered into a license and collaboration agreement (the “Harbour License Agreement”) with Harbour BioMed US Inc. ("Harbour"), pursuant to which Harbour granted us an exclusive license for the development, manufacturing and commercialization of CLN-418 in the U.S. Under the terms of the Harbour License Agreement, we paid Harbour an upfront license fee of $25.0 million in February 2023.
19
In May 2023, we entered into an agreement with Cowen and Company, LLC (“Cowen”) to establish an at-the-market equity offering program (the "ATM"), pursuant to which we may offer and sell up to $125.0 million of our common stock from time to time through Cowen, acting as our sales agent. In the three months ended June 30, 2023, we sold approximately 3.3 million shares under the ATM and received net proceeds of $38.4 million, after deducting commissions. As of June 30, 2023, we had $85.6 million in shares of our common stock remaining under the ATM.
Comparison of the Six Months Ended June 30, 2023 and 2022
The following table summarizes our sources and uses of cash for the six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Net cash used in operating activities |
|
$ |
(82,003 |
) |
|
$ |
(47,328 |
) |
Net cash provided by investing activities |
|
|
27,294 |
|
|
|
335,563 |
|
Net cash provided by financing activities |
|
|
40,391 |
|
|
|
5,554 |
|
Net increase (decrease) in cash and cash equivalents |
|
$ |
(14,318 |
) |
|
$ |
293,789 |
|
Cash Flow from Operating Activities
For the six months ended June 30, 2023, operating activities used $82.0 million of cash, which primarily consisted of our operating expenses of $100.4 million and a $3.5 million net change in our operating assets and liabilities, partially offset by net non-cash charges of $11.8 million and interest income of $9.8 million. The net non-cash charges primarily consisted of $15.2 million of equity-based compensation expense, partially offset by $3.5 million in accretion on our marketable securities. The net change in our operating assets and liabilities included $4.7 million for income taxes paid during the period.
For the six months ended June 30, 2022, operating activities used $47.3 million of cash, which primarily consisted of our operating expenses of $69.8 million and income tax expense of $46.5 million, partially offset by a benefit of $51.1 million from the net change in our operating assets and liabilities, non-cash charges of $17.2 million and interest income of $0.9 million. The non-cash charges primarily consisted of $15.2 million of equity-based compensation expense and $1.7 million in amortization on our marketable securities.
Cash Flow from Investing Activities
For the six months ended June 30, 2023, net cash provided by investing activities was $27.3 million, which primarily consisted of proceeds of $198.1 million from the sales and maturities of marketable securities, partially offset by $170.6 million used for the purchase of marketable securities.
For the six months ended June 30, 2022, net cash provided by investing activities was $335.6 million, which consisted of $270.0 million of proceeds from the sale of Cullinan Pearl, net of $5.0 million in escrow, and $158.9 million from the sales and maturities of investments, partially offset by the purchase of $93.4 million of investments.
Cash Flow from Financing Activities
For the six months ended June 30, 2023, net cash provided by financing activities was $40.4 million, which primarily consisted of $38.4 million of net proceeds from the issuance of common stock under our ATM, and $1.8 million from the issuance of a convertible note by Cullinan MICA to a noncontrolling interest.
For the six months ended June 30, 2022, net cash provided by financing activities was $5.6 million, which primarily consisted of $4.4 million from stock option exercises and $1.2 million from the issuance of noncontrolling interests.
Future Funding Requirements
We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we advance the preclinical activities, manufacturing and clinical trials of our product candidates. In addition, we have and will continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. Our expenses will also increase as we:
•continue our research and development efforts and submit INDs for our product candidates and programs;
•conduct preclinical studies and clinical trials for our current and future product candidates;
•experience any delays or encounter any issues with any of the above, including but not limited to failed studies or trials, complex results, safety issues, or other regulatory challenges;
•develop the necessary processes, controls, and manufacturing capabilities to obtain marketing approval for our product candidates and to support manufacturing on a commercial scale;
20
•develop and implement plans to establish and operate in-house manufacturing operations and facilities, if deemed appropriate;
•seek regulatory approvals for any product candidates that successfully complete clinical trials;
•hire and retain additional personnel, such as non-clinical, clinical, pharmacovigilance, quality assurance, regulatory affairs, manufacturing, distribution, legal, compliance, medical affairs, finance, general and administrative, commercial, and scientific personnel; and
•develop, maintain, expand, and protect our intellectual property portfolio.
Based on our current operational plans and assumptions, we expect that our current cash, cash equivalents, and short-term and long-term investments will be sufficient to fund operations through at least twelve months from the date of issuance of our consolidated financial statements. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. As we progress with our development programs and the regulatory review process, we expect to incur significant expenses related to product manufacturing, pre-commercial activities and commercialization. We may also require additional capital to pursue in-licenses or acquisitions of other programs to further expand our pipeline.
Because of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates and programs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
•the scope, progress, results, and costs of drug discovery, laboratory testing and preclinical and clinical development for our current and future product candidates;
•timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;
•the prevalence, duration and severity of potential side effects or other safety issues experienced by patients receiving our product candidates or future product candidates;
•our ability to establish and maintain collaborations and license agreements on favorable terms, if at all, and the extent to which we acquire or in-license technologies or programs, if at all;
•our ability to enroll clinical trials in a timely manner and to quickly resolve any delays or clinical holds that may be imposed on our development programs;
•the costs of expanding our facilities to accommodate our expected growth in personnel;
•our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate, and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices;
•the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;
•the extent to which we acquire or in-license technologies or programs;
•the sales price and availability of adequate third-party coverage and reimbursement for our product candidates, if and when approved; and
•the ongoing costs of operating as a public company.
Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements, and other collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity, current ownership interests will be diluted. If we raise additional funds through government or third-party funding, collaboration agreements, strategic alliances, licensing arrangements, or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.
21
Contractual Obligations and Other Commitments
We have certain payment obligations under various license and collaboration agreements. Under these agreements, we are required to make milestone payments upon successful completion and achievement of certain intellectual property, clinical, regulatory, and sales milestones. The payment obligations under the license and collaboration agreements are contingent upon future events, such as our achievement of specified development, clinical, regulatory, and commercial milestones, and we will be required to make milestone and royalty payments in connection with the sale of products developed under these agreements. As the achievement and timing of these future milestone payments are not probable or estimable, such amounts have not been included in our consolidated balance sheets as of June 30, 2023 and December 31, 2022.
As of June 30, 2023, total future minimum lease payments were $5.1 million with $2.0 million payable within twelve months. See Note 12 to our consolidated financial statements included in this Quarterly Report on Form 10-Q for further detail on our lease obligations and the timing of expected future payments.
In addition, we enter into agreements in the normal course of business with CROs for clinical trials and with other vendors for preclinical studies, manufacturing services, and other services and products for operating purposes, which are generally cancelable upon written notice.
Critical Accounting Policies and Estimates
Our critical accounting policies have not materially changed from those described in the 2022 10-K, except for our accounting policy for equity-based compensation.
Equity-Based Compensation
We measure the fair value of market-based RSUs on the grant date using a Monte Carlo simulation model. We estimate the fair value of stock options using the Black-Scholes option pricing model. Both the Monte Carlo simulation model and the Black-Scholes option pricing model require the input of objective and subjective assumptions. Certain assumptions used, including our expected stock price volatility, involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, equity-based compensation expense could be materially different for future awards.
Prior to 2023, the expected volatility used in the Black-Scholes option pricing model for new options was based on historical volatilities of the stock prices of similar entities within our industry over a period of time commensurate with the expected term assumption. In 2023, we determined that a sufficient amount of historical information was available regarding the volatility of our stock price to begin using a blended rate that combines our historical volatility with the historical volatilities of the stock prices of similar entities within our industry over a period of time commensurate with the expected term assumption.
Emerging Growth Company Status
In April 2012, the Jumpstart Our Business Startups Act (the “JOBS Act") was enacted. Section 107 of the JOBS Act provides that an "emerging growth company" ("EGC") can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early.
We will remain an emerging growth company until the earliest to occur of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.
Recently Issued and Adopted Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 of our consolidated financial statements included in this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Information required by this Item is not applicable as we are electing scaled disclosure requirements available to smaller reporting companies with respect to this Item.
22
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We have established disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (as amended, the “Exchange Act”), designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of June 30, 2023, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies our judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective at the reasonable assurance level as of June 30, 2023.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, that occurred during the fiscal quarter ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
23
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors.
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 10-K"), which could materially affect our business, financial condition or future results. The risk factors disclosure in our 2022 10-K is qualified by the information that is described in this Quarterly Report on Form 10-Q. The risks described in our 2022 10-K are not our only risks. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial also may materially adversely affect our business, financial condition or future results.
24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Use of Proceeds from IPO of Common Stock
On January 7, 2021, our Registration Statement on Form S-1, as amended (Registration No. 333-251512), was declared effective by the Securities Exchange Commission (the "SEC") for our initial public offering ("IPO"). The aggregate net proceeds to us from our IPO, after underwriting discounts and offering expenses, were $264.5 million. As of June 30, 2023, we have used $114.1 million of the net proceeds from the IPO. We have invested the unused net proceeds from the IPO into money market funds and marketable securities. Information related to use of proceeds from registered securities is incorporated herein by reference to the “Use of Proceeds” section of our IPO as described in our final prospectus dated January 7, 2021 and filed with the SEC on January 11, 2021 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. There has been no material change in the planned use of proceeds as described in our final prospectus.
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Not applicable.
25
Item 6. Exhibits.
|
|
|
Exhibit Number |
|
Description |
|
|
|
3.1 |
|
Second Amended and Restated Certificate of Incorporation of the Registrant, as amended by the Certificate of Amendment, effective as of February 25, 2021 (incorporated by reference to Exhibit 3.1 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 30, 2021). |
|
|
|
3.2 |
|
Second Amended and Restated Bylaws of the Registrant, effective as of February 25, 2021 (incorporated by reference to Exhibit 3.2 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 30, 2021). |
|
|
|
3.3 |
|
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed with the SEC on January 19, 2023). |
|
|
|
10.1* |
|
Consulting Agreement, dated June 8, 2023, by and between the Registrant and Patrick Baeuerle |
|
|
|
10.2* |
|
Non-Employee Director Compensation Policy |
|
|
|
31.1* |
|
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
31.2* |
|
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
32.1** |
|
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
101.INS |
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
|
|
|
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
|
|
|
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
104 |
|
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, has been formatted in Inline XBRL and contained in Exhibit 101. |
* Filed herewith.
** The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.
26
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
Cullinan Oncology, Inc. |
|
|
|
|
Date: August 10, 2023 |
|
By: |
/s/ Nadim Ahmed |
|
|
|
Name: Nadim Ahmed |
|
|
|
Title: President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
|
|
|
Date: August 10, 2023 |
|
By: |
/s/ Jeffrey Trigilio |
|
|
|
Name: Jeffrey Trigilio |
|
|
|
Title: Chief Financial Officer (Principal Financial and Accounting Officer) |
|
|
|
|
27
Exhibit 10.1
CONSULTING AGREEMENT
This Consulting Agreement (the “Agreement”) is made as of June 8, 2023 (the “Effective Date”) by and between Cullinan Oncology, Inc., a Delaware corporation with principal offices at One Main Street, Suite 1350, Cambridge, MA 02141 and on behalf of its affiliates and subsidiaries (collectively “Cullinan”) and Patrick Baeuerle, PhD, (“Consultant”). Cullinan and Consultant may be referred to herein individually as a “Party” and collectively as the “Parties”.
WHEREAS, the Parties entered into a Service Agreement effective as of the closing of the Cullinan’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (“Service Agreement”); and
WHEREAS, the Parties have mutually agreed to terminate the Service Agreement for purposes beneficial to both Parties and desire to replace the Service Agreement with this Agreement upon the Effective Date.
1. Engagement of Services. Consultant agrees to provide temporary consulting services to Cullinan as described in Exhibit A hereto (collectively, the “Services”) during the Term (as defined herein) of this Agreement. Consultant may not subcontract or otherwise delegate his obligations under this Agreement without Cullinan’s prior written consent. Consultant agrees and affirms that he shall comply fully with all applicable laws, rules and regulations governing such Services, as well as with any applicable policies of Cullinan.
1.1 Title. Consultant shall be referred to in Cullinan’s publicly facing documents and presentations as Co-Founder, Chief Scientific Advisor.
1.2 Third Party Board Participation. The Consultant may serve on boards of directors other than Cullinan’s, provided Consultant obtains prior written consent from an officer of Cullinan before committing to serve in such capacity.
2. Compensation. As sole compensation for the performance of the Services, Cullinan will pay to Consultant the amount(s) specified in Exhibit A hereto (the “Compensation”). Consultant shall be entitled to receive reimbursement for all reasonable expenses incurred by the Consultant during the Term in performing Services hereunder, (i) subject to Cullinan’s approval and (ii) in accordance with Cullinan’s travel and expense policies and procedures.
2.1 Tax Compliance. Consultant understands that as a non-US resident, he is subject to potential withholding tax under US law. Consultant agrees to furnish Forms W-8 as requested by Cullinan from time to time and to be bound by withholding requirements as determined under Form W-8. Consultant agrees to cooperate with Cullinan with respect to furnishing any requested tax information related to Cullinan’s tax obligations under law and to indemnify Cullinan to the extent it incurs any tax liability as a result of this Agreement.
2.2 No Additional Consulting Benefits. Consultant agrees that he shall provide the Services in exchange for the Compensation described in this Section 2 and that he is not entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical or pension payments, made available to employees of the Company or any other consideration or benefits from the Company for the performance of the Services.
3. Equipment. During the Term, Cullinan may provide to Consultant on a loaned basis and without charge: (i) use of certain computer equipment along with certain Cullinan software (the "IT Equipment") as deemed necessary by Cullinan to facilitate the consulting relationship hereunder, and (ii) access, and technical support in connection with such access, to Cullinan’s data, files, database(s), e-mail system, and other electronic systems (the "IT Infrastructure") as deemed necessary by Cullinan to facilitate the contracting relationship hereunder. Consultant acknowledges that the IT Equipment and the IT Infrastructure are made available to Consultant by Cullinan solely for purposes related to the provision of the Services described herein and that his use of the IT Equipment and IT Infrastructure is subject to the provisions of this Agreement, including Section 4 hereof, and to any other applicable policy of Cullinan.
4. Independent Contractor/No Employment Relationship. Consultant’s relationship with Cullinan will be that of an independent contractor. No relationship of employer and employee, or partners, or joint venturers, or agent and principal shall be created by this Agreement.
4.1 Scope of Authority. Consultant shall not be authorized to transact business, incur obligations, sell goods, receive payments solicit orders or assign or create any obligation of any kind, express or implied, or make any other representation or enter into any contract or commitment on behalf of Cullinan, unless expressly authorized to do so in writing by Cullinan.
4.2 Performance of Services. Consultant shall have the right to control and determine the methods, manner and means of performing the Services. In performing the Services, the amount of time devoted by Consultant on any given day will be entirely within Consultant’s control, and Cullinan will rely on Consultant to put in the amount of time as is necessary to fulfill the requirements of this Agreement, provided Cullinan has a general right of inspection and supervision to secure their satisfactory completion.
4.2 Compliance with Applicable Laws. Consultant’s relationship with Cullinan being that of an independent contractor, Consultant shall be barred from making any claim against Cullinan for disability coverage, health and dental coverage, minimum wage, insurance coverage, unemployment insurance benefits, vacation pay, sick leave, or any other employee benefit of any kind and Consultant shall not be entitled to any of the benefits that Cullinan may make available to its employees. Cullinan will not withhold or make payments for social security, make unemployment insurance or disability insurance contributions, or obtain worker’s compensation insurance on Consultant’s behalf. Consultant accepts exclusive liability for complying with all applicable state and federal laws governing self-employed individuals and for making payments corresponding thereto and Consultant acknowledges and agrees that the Consultant is fully responsible for all such matters and shall indemnify Cullinan as well as its successor companies, affiliates and subsidiaries (“Cullinan Indemnitees”) for any costs incurred by Cullinan Indemnitees or arising as a result of Consultant’s failure to make such payments, remittances or withholdings, including without limitation penalties and interest.
4.3 Non-Exclusivity. Consultant retains the right to contract with other companies or entities for full or part time employment or consulting services, without restriction, provided, however, that Consultant remains in compliance with the terms of the Confidentiality, Assignment and Non-solicitation Agreement that Consultant previously executed for the benefit of the Company and which remains in full force and effect. Likewise, the Company retains a reciprocal right to contract with other companies and/or individuals for consulting services without restriction.
5. Confidential Information Protections.
5.1 Nondisclosure; Recognition of Cullinan’s Rights. Consultant acknowledges that his relationship with Cullinan is one of high trust and confidence and that in the course of his services to Cullinan he has had and will continue to have access to Confidential Information (defined below). At all times during and after Consultant’s performance of Services for Cullinan and after expiration or termination of this Agreement, Consultant will hold in confidence and will not disclose, use, lecture upon, or publish any Cullinan Confidential Information, except as may be required in connection with its work for Cullinan, or as expressly authorized by Cullinan. Consultant will obtain written approval by an officer of Cullinan before publishing or submitting for publication any material (written, oral, or otherwise) that relates to his work at Cullinan and/or incorporates any Cullinan Confidential Information. Consultant hereby assigns to Cullinan any and all rights Consultant may have or acquire in any and all Confidential Information and recognizes that all Confidential Information shall be the sole and exclusive property of Cullinan and its assigns.
5.2 Confidential Information. The term “Confidential Information” shall mean any and all confidential knowledge, data or information related to Cullinan’s business or its or their actual or demonstrably anticipated research or development, including without limitation (a) trade secrets, inventions, ideas, processes, computer source and object code, data, formulae, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques; (b) tangible and intangible information relating to gene sequences, biological materials such as cell lines, antibodies, tissue samples, proteins, nucleic acids and the like, assays and assay components, chemical structures and analysis, and media, procedures and formulations for producing any such assays or assay components, and pre-clinical and clinical data, results, developments or experiments; (c) patents or patent applications, information regarding products, services, plans for research and development, marketing and business plans, budgets, financial statements, contracts, prices, suppliers, and customers; (d) information regarding the skills and compensation of Cullinan employees, contractors, and any other service providers of Cullinan; (e) the existence of any business discussions, negotiations, or agreements between Cullinan and any third party; and (f) information or data stored in or accessed from Cullinan’s software applications, or third party hosted software applications, and systems to which Consultant has access.
Consultant agrees that all files, documents, letters, memoranda, reports, records, data sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible material containing Confidential Information, whether created by Consultant or others, which shall come into Consultant’s custody or possession, shall be and are the exclusive property of Cullinan to be used by Consultant only in the performance of his duties for Cullinan and shall not be copied or removed from Cullinan premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of Consultant shall be delivered to the Cullinan, upon the earlier of (i) a request by the Company or (ii) the termination of this Agreement. After such delivery, Consultant shall not retain any such materials or copies thereof or any such tangible property.
5.3 Third Party Information. Consultant understands that Cullinan has received and will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on Cullinan’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During and after the Term, Consultant will hold Third Party Information in strict confidence and will not disclose to anyone (other than personnel of Cullinan who need to know such information in connection with their work for Cullinan) or use, Third Party Information, except in connection with the provision of Services for Cullinan or unless expressly authorized by an officer of Cullinan in writing.
5.4 No Improper Use of Information of Prior Employers and Others. Consultant represents that his performance of Services for Cullinan does not and will not breach any agreement with his current or former employer, including any non-compete agreement or any agreement to keep in confidence or refrain from using information acquired by him prior to his performance of the Services for Cullinan. Consultant further represents that Consultant has not entered into, and will not enter into, any agreement, either written or oral, that conflicts with the obligations under this Agreement. During his performance of Services for Cullinan, Consultant will not improperly make use of, or disclose, any information or trade secrets of any former employer or other third party, nor will Consultant bring onto the premises of Cullinan or use any unpublished documents or any property belonging to any current or former employer or other third party, in violation of any lawful agreements with any current or former employer or third party. Consultant will use in the performance of his duties only information that is generally known and used by persons with training and experience comparable to his own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by Cullinan.
5.5 Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. Consultant agrees to be bound by all such obligations and restrictions that are known to Consultant and to take all action necessary to discharge the obligations of the Company under such agreements.
5.6 Consultant’s obligations under this Section 5 shall not apply to any information that (i) is or becomes known to the general public under circumstances involving no breach by Consultant or others of the terms of this Section 5, (ii) is generally disclosed to third parties by Cullinan without restriction on such third parties, or (iii) is approved for release by written authorization of an officer of Cullinan. Further, nothing herein prohibits Consultant from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies or participating in government agency investigations or proceedings. In addition, notwithstanding Consultant’s confidentiality and nondisclosure obligations, Consultant is hereby advised as follows pursuant to the Defend Trade Secrets Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.”
6. Inventions.
6.1 Definitions. As used in this Agreement, the term “Invention” means any ideas, concepts, information, materials, processes, data, programs, know-how, modifications, improvements, discoveries, developments, designs, artwork, formulae, other copyrightable works, and techniques and all Intellectual Property Rights in any of the items listed above. The term “Intellectual Property Rights” means all trade secrets, copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country. The term “Moral Rights” means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.
6.2 Disclosure and Assignment of Cullinan Inventions. Consultant agrees to make full and prompt disclosure to Cullinan of all inventions, creations, improvements, enhancements, designs, innovations, discoveries, processes, methods, techniques, developments, software, computer programs, and works of authorship, whether or not patentable and whether or not copyrightable, that are created, made, conceived or reduced to practice by Consultant or under his direction or jointly with others (i) during the Term if made for the Company in the course of the performance of the Services hereunder or (ii) during or after the Term if resulting or derived from Confidential Information, whether or not during normal working hours or on the premises of Cullinan.
Inventions assigned to Cullinan or to a third party as directed by Cullinan pursuant to the subsection titled “Government or Third Party” are referred to in this Agreement as “Cullinan Inventions.” Subject to the subsection titled “Government or Third Party”, Consultant hereby assigns and agrees to assign in the future (when any such Inventions or Intellectual Property Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to Cullinan all right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by him, either alone or with others, during the period of my performance of Services for Cullinan and during the term of this Agreement with Cullinan. Any assignment of Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Cullinan and to the extent the following is allowed by the laws in any country where Moral Rights exist, Consultant hereby unconditionally and irrevocably waives the enforcement of such Moral Rights, and all claims and causes of action of any kind against Cullinan or related to Cullinan’s customers, with respect to such rights. Consultant further acknowledges and agrees that neither his successors-in-interest nor legal heirs retain any Moral Rights in any Inventions (and any Intellectual Property Rights with respect thereto).
6.3 Obligation to Keep Cullinan Informed. During the period of performance of Services for Cullinan and during the Term of this Agreement, and for one (1) year after his performance of Services for Cullinan and this Agreement ends, Consultant will promptly and fully disclose to Cullinan in writing (a) all Inventions authored, conceived, or reduced to practice by him, either alone or with others and (b) all patent applications filed by Consultant or in which Consultant is named as an inventor or co-inventor.
6.4 Government or Third Party. Consultant agrees that, as directed by Cullinan, Consultant will assign to a third party, including without limitation the United States, all of his right, title, and interest in and to any particular Cullinan Invention.
6.5 Cooperation during Patent Prosecution. Consultant agrees to cooperate fully with Cullinan, both during and after the Consultation Period, with respect to the procurement, maintenance, and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Inventions that occurred or were initiated during the Consultation Period. Consultant shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which Cullinan may deem necessary or desirable in order to protect its rights and interests in any Invention. Consultant further agrees that if Cullinan is unable, after reasonable effort, to secure the signature of Consultant on any such papers, any executive officer of Cullinan shall be entitled to execute any such papers as the agent and the attorney-in-fact of Consultant, and Consultant hereby irrevocably designates and appoints each executive officer of Cullinan as Consultant’s agent and attorney-in-fact to execute any such papers on Consultant’s behalf, and to take any and all actions as Cullinan may deem necessary or desirable in order to protect its rights and interests in any Invention, under the conditions described in this sentence.
6.6 Litigation, Investigation and Regulatory Cooperation and Assistance. During and after the period of Consultant’s performance of the Services on behalf of Cullinan, and at Cullinan’s request and expense, Consultant shall cooperate fully with Cullinan, including in (i) the defense or prosecution of any claims or actions, including without limitation enforcement of United States or Foreign Intellectual Property Rights and Moral Rights relating to Cullinan’s Inventions, now in existence or which may be brought in the future against or on behalf of Cullinan which relate to events or occurrences that transpired while the Consultant was engaged by Cullinan, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Consultant may have knowledge or information. The Consultant’s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of Cullinan at mutually convenient times. During and after Consultant’s performance of the Services, Consultant shall also cooperate fully with Cullinan in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was engaged by the Company. The Company shall reimburse Consultant for any reasonable out-of-pocket expenses incurred in connection with the Consultant’s performance of his obligations pursuant to this Section 6.6. If Cullinan is unable to secure his signature on any document needed in connection with such purposes, Consultant hereby irrevocably designates and appoints Cullinan and its duly authorized officers and agents as Consultant’s agent and attorney in fact, which appointment is coupled with an interest, to act on Consultant’s behalf to execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as if executed by him.
7. Records. Consultant agrees to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Cullinan) of all Inventions made by Consultant during the period of my performance of Services for Cullinan, which records shall be available to, and remain the sole property of, Cullinan at all times.
8. Termination; Non-Solicitation; Return of Cullinan Property.
8.1 Term. This Agreement shall govern all Services that Consultant provides to Cullinan commencing on the Effective Date and ending on December 31, 2024 (hereinafter the “Term”) unless earlier terminated as provided herein. This Agreement will automatically renew and extend for one-year periods beginning on January 1, 2025, each constituting a subsequent Term, unless earlier terminated as provided herein.
8.2 Termination of Agreement. Either Party may terminate this Agreement for convenience, for any or no reason, at any time upon one hundred eighty (180) calendar days’ prior written notice to the other Party, unless otherwise mutually agreed by the Parties. Either Party may terminate this Agreement upon written notice to the other Party if the other Party breaches this Agreement and does not cure the breach within thirty (30) calendar days following receipt of written notice thereof from the non-breaching Party. Such right to terminate this Agreement for breach shall be in addition to any other remedies available to the terminating Party at law. In case of the termination of this Agreement in accordance with Section 8 hereof, Consultant shall not be entitled to receive any termination pay, severance pay, or any damages or other payments arising from the termination of this Agreement, other than the unpaid Annual Compensation effectively earned up to the date of termination of this Agreement, if any, and any reimbursement of any non-cancellable expenses accrued prior to the date of termination.
8.3 Non-Solicitation and Non-Interference with Business. After the Effective Date and during the Term and for the period of one (1) year immediately following expiration of this Agreement or earlier termination of this Agreement, the Consultant shall not, on his own behalf or on behalf of, or in connection with, any other person, directly or indirectly, in any capacity whatsoever, including as an employer, employee, principal, agent, joint venturer, partner, shareholder or other equity holder, independent contractor, consultant, licensor, licensee, franchiser, franchisee, distributor, supplier or trustee or by and through any person or otherwise: (a) employ, offer employment to, recruit, or solicit for employment any individual who is employed by Cullinan or who has resigned within the preceding three months from Cullinan, or solicit or induce, or attempt to induce, any employee of Cullinan to terminate their employment relationship with Cullinan, whether or not such individual would thereby commit any breach of any contract or terms of employment; (b) solicit or induce, or attempt to induce, any contractor or consultant of Cullinan to terminate its consulting arrangement or otherwise cease its relationship with Cullinan, whether or not such contractor or consultant would thereby commit any breach of any contract; or (c) interfere or attempt to interfere with the business of Cullinan or persuade or attempt to persuade, solicit, divert or take away, or attempt to divert or to take away, any customer, prospective customer or supplier of Cullinan or alter in an adverse manner such person's relationship with Cullinan.
8.4 Return of Cullinan Property. Except as otherwise directed by Cullinan in writing, upon expiration or termination of this Agreement, Consultant will return to Cullinan all tangible Cullinan property provided or loaned to Consultant hereunder, including but not limited to the IT Equipment, and Consultant's access to the IT Infrastructure shall be thereafter terminated. Further upon expiration or termination of the Agreement, or earlier as requested by Cullinan, Consultant will deliver to Cullinan any and all drawings, notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Cullinan Invention, Third Party Information, or Confidential Information and cooperate in any manner requested by Cullinan to return Cullinan property.
8.5 Survival. The following provisions shall survive termination of this Agreement: Sections 4 – 9.
9. General Provisions.
9.1 Indemnification. Consultant shall indemnify, defend and hold Cullinan, its affiliates and subsidiaries and their officers, directors, employees and agents harmless from and against any and all claims, charges, demands, suits, causes or rights of action, liabilities, losses, damages, costs, fees and/or expenses, of any nature whatsoever (including reasonable attorneys' fees, court costs and out-of-pocket expenses) suffered or incurred by Cullinan and its affiliates and subsidiaries arising from the rendering of the Services by the Consultant.
9.2 Governing Law, Jurisdiction. This Agreement shall be governed, including as to validity, interpretation and effect, by the laws of the state of Delaware as applied to transactions taking place wholly within the state of Delaware regardless of where Consultant may perform Services. Consultant explicitly waives any causes of actions or remedies he may have with respect to the laws of any jurisdiction other than the state of Delaware.
9.3 Severability. In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal, or unenforceable provision had never been contained herein. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity, or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.
9.4 Opportunity to Obtain Legal Advice. The Parties acknowledge that they have read and negotiated this Agreement, and have discussed and have been afforded a reasonable opportunity to obtain independent legal advice and consider the meaning and effects of this Agreement.
9.5 Assignment, Binding Effect. This Agreement may not be assigned by Consultant without Cullinan’s consent, and any such attempted assignment shall be void and of no effect. Consultant hereby recognizes being personally bound by the obligations contained herein and agrees that the terms and provisions of this Agreement shall be binding upon his heirs, executors, administrators and representatives.
9.6 Notices. All notices, requests, and other communications under this Agreement must be in writing and must be mailed by registered or certified mail, postage prepaid and return receipt requested, delivered by hand, sent by internationally-recognized courier service, or sent by receipted electronic mail, to the Party to whom such notice is required or permitted to be given. If mailed, any such notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by hand or internationally-recognized courier service, any such notice will be considered to have been given when received by the Party to whom notice is given, as evidenced by written and dated receipt of the receiving Party or by written confirmation of delivery by such internationally-recognized courier service, respectively. If sent by electronic mail, which if sent by Consultant shall be sent to legal@cullinanoncology.com, such notice will be considered to have been given upon receipt by the sending Party of receiving Party’s written confirmation of receipt of such notice. The mailing address for notice to either Party will be the address shown on the first page of this Agreement. Either Party may change its mailing address by notice as provided by this section.
9.7 Legal Fees. If any dispute arises between the Parties with respect to the matters covered by this Agreement which leads to a proceeding to resolve such dispute, the prevailing Party in such proceeding shall be entitled to receive its reasonable attorneys’ fees, expert witness fees, and out-of-pocket costs incurred in connection with such proceeding, in addition to any other relief it may be awarded.
9.8 Injunctive Relief. A breach of any of the promises or agreements contained in this Agreement may result in irreparable and continuing damage to Cullinan for which there may be no adequate remedy at law, and Cullinan is therefore entitled to seek injunctive relief, with any requirement for the securing or posting of any bond in connection with seeking such relief hereby being waived, as well as such other and further relief as may be appropriate.
9.9 Waiver. No waiver by Cullinan of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by Cullinan of any right under this Agreement shall be construed as a waiver of any other right. Cullinan shall not be required to give notice to enforce strict adherence to all terms of this Agreement.
9.10 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The Parties shall be entitled to rely upon delivery of an executed facsimile or similar executed electronic copy of this Agreement, and such facsimile or similar executed electronic copy shall be legally effective to create a valid and binding agreement between the Parties.
9.11 Entire Agreement. This Agreement is the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof. This Agreement supersedes all prior discussions between the Parties regarding the subject matter hereof. For sake of clarity, the Parties agree this Agreement supersedes and cancels in all respects all prior agreements, including without limitation the Service Agreement, promises, and understandings, oral or written, between Consultant and Cullinan, with the exception of the Confidentiality, Assignment and Non-Solicitation Agreement previously executed by the Parties, which shall remain in full force and effect. The terms of this Agreement will govern all Services undertaken by Consultant for Cullinan.
9.12. Modification. This Agreement may be amended or modified only by written instrument executed by both Consultant and Cullinan. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by both Parties.
In Witness Whereof, the Parties have caused this Agreement to be executed as of the Effective Date set forth above.
|
|
|
|
|
|
|
Cullinan Oncology, Inc. |
|
Patrick Baeuerle, PhD |
|
By: |
/s/ Steve Andre |
|
By: |
/s/ Patrick Baeuerle |
|
Name: |
Steve Andre |
|
Name: |
Patrick Baeuerle |
|
Title: |
Chief Human Resources Officer |
|
Title: |
CSO, Biologics |
|
Date: |
June 8, 2023 |
|
Date: |
June 12, 2023 |
|
EXHIBIT A
1. Services:
Location:
•Consultant will perform the Services from Germany, and will travel to the United States to perform Services at the request of the Company, generally not to exceed once per month.
Services:
•Consultant shall provide the following Services, as requested by Cullinan:
oServe as Chair of Cullinan’s Scientific Advisory Board
oIn investor and analyst meetings and calls, and medical conferences, cover, as requested by Cullinan, all aspects of target biology and expression, drug design, manufacturing, mode of action, and preclinical safety and efficacy data for Cullinan’s pipeline
oKeep abreast of competitive landscape and understand all competitor programs, and provide advice to Cullinan thereon
oPublish CGEM’s data in reputed journals and as posters and/or oral presentations at significant scientific and industry conferences
oRepresent Cullinan Oncology at key industry meetings/panels
oHelp identify and assess in-licensing opportunities with compelling preclinical data and, as appropriate, clinical data
oContribute to and review pitch decks describing new and existing programs
oEngage in drafting and reviewing IND-enabling documents
oHelp IP/legal with CGEM’s IP strategy, and ongoing patent efforts
oProvide advice with prioritization of early pipeline
oHelp optimize biomarker programs across all studies
oHelp analyze and interpret clinical efficacy, safety from clinical programs, in context of translational analyses, including biomarker data, PK and PD study results
oHelp create hypotheses for further studies
oProvide advice with regard to selection of indications and combination therapies
oProvide advice with regard to competing programs
oPropose additional lab work to fully understand MoA and safety signals
oParticipate in Cullinan Leadership Team (“CLT”) meetings and serve as advisor to CLT
oOther deliverables, as requested by Cullinan
2. Compensation:
Consultant shall be paid $40,556.25 per month for a maximum total amount not to exceed $480,000 per calendar year (the “Annual Compensation”) for the Term of this Agreement, except with Cullinan’s prior written approval.
Subject to the criteria set forth below, Consultant shall be eligible to receive a bonus payment in the amount of 40% of the Annual Compensation, payable in the first quarter of 2024, for services performed throughout calendar year 2023. For subsequent calendar years, and subject to the criteria set forth below, Consultant shall be eligible to receive a bonus payment in the amount of 25% of the Annual Compensation, payable in the first quarter of a calendar year for Services performed the preceding calendar year. Eligibility for any bonus payment shall be contingent on Consultant having attended and participated in, to Cullinan’s satisfaction, 75% of those investor and analyst meetings and medical conferences that an officer of Cullinan invited Consultant to attend, and 100% of Scientific Advisory Board meetings in the relevant calendar year.
Exhibit 10.2
CULLINAN ONCOLOGY, INC.
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Cullinan Oncology, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”). This Policy is effective as of the adoption date set forth below (the “Effective Date”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below:
Cash Retainers
Annual Retainer for Board Membership: $40,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro- rated based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors.
|
|
Additional Annual Retainer for Non-Executive Chair: |
$33,000 |
Additional Annual Retainers for Committee Membership: |
|
Audit Committee Chair: |
$15,000 |
Audit Committee member: |
$7,500 |
Compensation Committee Chair: |
$10,000 |
Compensation Committee member: |
$5,000 |
Nominating and Corporate Governance Committee Chair: |
$10,000 |
Nominating and Corporate Governance Committee member: |
$5,000 |
Chair and committee member retainers are in addition to retainers for members of the Board of Directors. No additional compensation will be paid for attending individual committee meetings of the Board of Directors.
Equity Retainers
Initial Award: An initial, one-time stock option award (the “Initial Award”) with a Value (as defined below) of $275,000 will be granted to each new Outside Director upon his or her election to the Board of Directors, which shall vest with respect to one-third (1/3) of the shares subject to such Initial Award on the first anniversary of the date of grant, with the remainder vesting thereafter in 24 equal monthly installments, provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. The Initial Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company’s 2021 Stock Option and Incentive Plan) of the Company’s common stock on the date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date.
Annual Award: On each date of each Annual Meeting of Stockholders of the Company following the Effective Date (the “Annual Meeting”), each continuing Outside Director, other than a director receiving an Initial Award, will receive an annual stock option award (the “Annual Award”) with a Value of $165,000, which shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Such Annual Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company’s 2021 Stock Option and Incentive Plan) of the Company’s common stock on the date of grant.
Value: For purposes of this Policy, “Value” means with respect to any stock option award, the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under Financial Accounting Standard Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718.
Sale Event Acceleration: All outstanding Initial Awards and Annual Awards held by an Outside Director shall become fully vested and exercisable or nonforfeitable upon a Sale Event (as defined in the Company’s 2021 Stock Option and Incentive Plan).
Expenses
The Company will reimburse all reasonable out-of-pocket expenses incurred by non- employee directors in attending meetings of the Board of Directors or any committee thereof.
Maximum Annual Compensation
The aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any Outside Director in a calendar year for services as an Outside Director period shall not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable Outside Director is initially elected or appointed to the Board of Directors; (or such other limits as may be set forth in Section 3(b) of the Company’s 2021 Stock Option and Incentive Plan or any similar provision of a successor plan). For this purpose, the “amount” of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions.
Adopted: January 7, 2021
Amended and Adopted: June 8, 2023
Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Nadim Ahmed, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Cullinan Oncology, Inc. (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
|
|
|
Date: August 10, 2023 |
|
By: |
/s/ Nadim Ahmed |
|
|
|
Nadim Ahmed |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Jeffrey Trigilio, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Cullinan Oncology, Inc. (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
|
|
|
Date: August 10, 2023 |
|
By: |
/s/ Jeffrey Trigilio |
|
|
|
Jeffrey Trigilio |
|
|
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cullinan Oncology, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
Date: August 10, 2023 |
|
By: |
/s/ Nadim Ahmed |
|
|
|
Nadim Ahmed |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
Date: August 10, 2023 |
|
By: |
/s/ Jeffrey Trigilio |
|
|
|
Jeffrey Trigilio |
|
|
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
v3.23.2
Document and Entity Information - shares
|
6 Months Ended |
|
Jun. 30, 2023 |
Jul. 31, 2023 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Period End Date |
Jun. 30, 2023
|
|
Document Fiscal Year Focus |
2023
|
|
Document Fiscal Period Focus |
Q2
|
|
Entity Registrant Name |
CULLINAN ONCOLOGY, INC.
|
|
Current Fiscal Year End Date |
--12-31
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Entity Central Index Key |
0001789972
|
|
Entity File Number |
001-39856
|
|
Entity Incorporation, State or Country Code |
DE
|
|
Entity Tax Identification Number |
81-3879991
|
|
Entity Address, Address Line One |
One Main Street
|
|
Entity Address, Address Line Two |
Suite 1350
|
|
Entity Address, City or Town |
Cambridge
|
|
Entity Address, Country |
MA
|
|
Entity Address, Postal Zip Code |
02142
|
|
City Area Code |
617
|
|
Local Phone Number |
410-4650
|
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
|
Trading Symbol |
CGEM
|
|
Security Exchange Name |
NASDAQ
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
true
|
|
Entity Ex Transition Period |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
42,734,644
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands |
Jun. 30, 2023 |
Dec. 31, 2022 |
Current assets: |
|
|
Cash and cash equivalents |
$ 141,834
|
$ 156,152
|
Short-term investments |
349,964
|
311,140
|
Prepaid expenses and other current assets |
6,437
|
7,180
|
Total current assets |
498,235
|
474,472
|
Property and equipment, net |
1,158
|
1,174
|
Operating lease right-of-use assets |
3,501
|
4,130
|
Other assets |
459
|
459
|
Long-term investments |
18,631
|
80,882
|
Total assets |
521,984
|
561,117
|
Current liabilities: |
|
|
Accounts payable |
2,493
|
2,660
|
Accrued expenses and other current liabilities |
15,531
|
14,135
|
Income tax payable |
0
|
4,282
|
Operating lease liabilities, current |
1,652
|
1,421
|
Total current liabilities |
19,676
|
22,498
|
Long-term liabilities: |
|
|
Operating lease liabilities, net of current portion |
2,734
|
3,590
|
Total liabilities |
22,410
|
26,088
|
Commitments and contingencies (Note 11) |
|
|
Stockholders' equity: |
|
|
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 647,500 and no shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively. |
0
|
0
|
Common stock, $0.0001 par value, 150,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 42,735,304 and 45,796,449 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively |
4
|
5
|
Additional paid-in capital |
639,066
|
585,320
|
Accumulated other comprehensive loss |
(1,625)
|
(2,601)
|
Accumulated deficit |
(137,871)
|
(47,695)
|
Total Cullinan stockholders' equity |
499,574
|
535,029
|
Noncontrolling interests |
0
|
0
|
Total stockholders' equity |
499,574
|
535,029
|
Total liabilities and stockholders' equity |
$ 521,984
|
$ 561,117
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AdditionalPaidInCapitalCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
+ Details
Name: |
us-gaap_MinorityInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 360 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(g)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
+ Details
Name: |
us-gaap_ShortTermInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 23 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 105 -SubTopic 10 -Section 65 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 105 -SubTopic 10 -Section 65 -Paragraph 6 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (e)(3) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 5 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(2) -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 848 -SubTopic 10 -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 17 -URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(3) -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(1) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(1) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_TaxesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Statement of Financial Position [Abstract] |
|
|
Preferred Stock par value |
$ 0.0001
|
$ 0.0001
|
Preferred Stock, shares authorized |
10,000,000
|
10,000,000
|
Preferred Stock, Share issued |
647,500
|
0
|
Preferred Stock, Shares Outstanding |
647,500
|
0
|
Common stock, par value |
$ 0.0001
|
$ 0.0001
|
Common stock, shares authorized |
150,000,000
|
150,000,000
|
Common stock, shares issued |
42,735,304
|
45,796,449
|
Common stock, shares outstanding |
42,735,304
|
45,796,449
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Income Statement [Abstract] |
|
|
|
|
Income (loss) from operations |
$ (37,605)
|
$ 239,679
|
$ (100,361)
|
$ 207,022
|
Operating expenses: |
|
|
|
|
Research and development |
27,391
|
26,411
|
79,487
|
50,947
|
General and administrative |
10,214
|
10,695
|
20,874
|
18,816
|
Total operating expenses |
37,605
|
37,106
|
100,361
|
69,763
|
Gain on sale of Cullinan Pearl |
0
|
276,785
|
0
|
276,785
|
Other income (expense): |
|
|
|
|
Interest income |
5,322
|
697
|
9,830
|
894
|
Other income (expense), net |
69
|
(241)
|
176
|
241
|
Net income (loss) before income taxes |
(32,214)
|
240,135
|
(90,355)
|
207,675
|
Income tax expense |
0
|
66,070
|
0
|
46,502
|
Net income (loss) |
(32,214)
|
174,065
|
(90,355)
|
161,173
|
Net loss attributable to noncontrolling interests |
(0)
|
(833)
|
(179)
|
(1,627)
|
Net income (loss) attributable to common stockholders of Cullinan |
(32,214)
|
174,898
|
(90,176)
|
162,800
|
Comprehensive income (loss): |
|
|
|
|
Net income (loss) |
(32,214)
|
174,065
|
(90,355)
|
161,173
|
Unrealized gain (loss) on investments |
(383)
|
(499)
|
976
|
(2,795)
|
Comprehensive income (loss) |
(32,597)
|
173,566
|
(89,379)
|
158,378
|
Comprehensive loss attributable to noncontrolling interests |
(0)
|
(833)
|
(179)
|
(1,627)
|
Comprehensive income (loss) attributable to Cullinan |
$ (32,597)
|
$ 174,399
|
$ (89,200)
|
$ 160,005
|
Net income (loss) per share: |
|
|
|
|
Basic |
$ (0.82)
|
$ 3.90
|
$ (2.24)
|
$ 3.65
|
Diluted |
$ (0.82)
|
$ 3.77
|
$ (2.24)
|
$ 3.51
|
Weighted-average shares used in computing net income (loss) per share: |
|
|
|
|
Weighted-average common stock outstanding - basic |
39,952
|
44,873
|
40,315
|
44,654
|
Diluted |
39,952
|
46,381
|
40,315
|
46,389
|
X |
- DefinitionEarnings net loss per share
+ References
+ Details
Name: |
cgem_EarningsNetLossPerShare |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGain( Loss) On Disposition Of Non Financial Assets.
+ References
+ Details
Name: |
cgem_GainLossOnDispositionOfNonFinancialAssets |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWeighted average shares used in computing earnings net loss per share
+ References
+ Details
Name: |
cgem_WeightedAverageSharesUsedInComputingEarningsNetLossPerShareAbstract |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTaxAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (e)(4) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 9: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (e)(4) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
+ Details
Name: |
us-gaap_InvestmentIncomeInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 25: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(2) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
+ Details
Name: |
us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingIncomeLossAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of income (expense) related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884
Reference 23: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(1) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 31: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands |
Total |
Preferred Stock |
Common Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Loss |
Accumulated Deficit |
Noncontrolling Interest in Subsidiaries |
Balances at Dec. 31, 2021 |
$ 425,374
|
|
$ 4
|
$ 584,714
|
$ (838)
|
$ (158,909)
|
$ 403
|
Balances, shares at Dec. 31, 2021 |
|
|
44,292,102
|
|
|
|
|
Net issuance of common stock under equity-based compensation plans |
(1,566)
|
|
|
(1,566)
|
|
|
|
Contributions from noncontrolling interests |
1,153
|
|
|
|
|
|
1,153
|
Net issuance of common stock under equity-based compensation plans, shares |
|
|
367,924
|
|
|
|
|
Equity-based compensation |
6,565
|
|
|
6,559
|
|
|
6
|
Unrealized gain (loss) on investments |
(2,296)
|
|
|
|
(2,296)
|
|
|
Net income (loss) |
(12,892)
|
|
|
|
|
(12,098)
|
(794)
|
Balances at Mar. 31, 2022 |
419,470
|
|
$ 4
|
592,839
|
(3,134)
|
(171,007)
|
768
|
Balances, shares at Mar. 31, 2022 |
|
|
44,660,026
|
|
|
|
|
Balances at Dec. 31, 2021 |
425,374
|
|
$ 4
|
584,714
|
(838)
|
(158,909)
|
403
|
Balances, shares at Dec. 31, 2021 |
|
|
44,292,102
|
|
|
|
|
Unrealized gain (loss) on investments |
(2,795)
|
|
|
|
|
|
|
Net income (loss) |
161,173
|
|
|
|
|
|
|
Balances at Jun. 30, 2022 |
604,618
|
|
$ 5
|
604,275
|
(3,633)
|
3,891
|
80
|
Balances, shares at Jun. 30, 2022 |
|
|
45,396,398
|
|
|
|
|
Balances at Mar. 31, 2022 |
419,470
|
|
$ 4
|
592,839
|
(3,134)
|
(171,007)
|
768
|
Balances, shares at Mar. 31, 2022 |
|
|
44,660,026
|
|
|
|
|
Net issuance of common stock under equity-based compensation plans |
(2,835)
|
|
$ (1)
|
(2,834)
|
|
|
|
Contributions from noncontrolling interests |
139
|
|
|
|
|
|
139
|
Net issuance of common stock under equity-based compensation plans, shares |
|
|
736,372
|
|
|
|
|
Equity-based compensation |
8,608
|
|
|
8,602
|
|
|
6
|
Unrealized gain (loss) on investments |
(499)
|
|
|
|
(499)
|
|
|
Net income (loss) |
174,065
|
|
|
|
|
174,898
|
(833)
|
Balances at Jun. 30, 2022 |
604,618
|
|
$ 5
|
604,275
|
(3,633)
|
3,891
|
80
|
Balances, shares at Jun. 30, 2022 |
|
|
45,396,398
|
|
|
|
|
Balances at Dec. 31, 2022 |
535,029
|
|
$ 5
|
585,320
|
(2,601)
|
(47,695)
|
0
|
Balances, shares at Dec. 31, 2022 |
|
|
45,796,449
|
|
|
|
|
Issuance of preferred stock in exchange for common stock, Share |
|
647,500
|
(6,475,000)
|
|
|
|
|
Issuance of preferred stock in exchange for common stock |
|
|
$ (1)
|
1
|
|
|
|
Net issuance of common stock under equity-based compensation plans |
(36)
|
|
|
(36)
|
|
|
|
Contributions from noncontrolling interests |
179
|
|
|
|
|
|
179
|
Net issuance of common stock under equity-based compensation plans, shares |
|
|
22,152
|
|
|
|
|
Equity-based compensation |
7,259
|
|
|
7,259
|
|
|
|
Unrealized gain (loss) on investments |
1,359
|
|
|
|
1,359
|
|
|
Net income (loss) |
(58,141)
|
|
|
|
|
(57,962)
|
(179)
|
Balances at Mar. 31, 2023 |
485,649
|
|
$ 4
|
592,544
|
(1,242)
|
(105,657)
|
0
|
Balances, shares at Mar. 31, 2023 |
|
647,500
|
39,343,601
|
|
|
|
|
Balances at Dec. 31, 2022 |
535,029
|
|
$ 5
|
585,320
|
(2,601)
|
(47,695)
|
0
|
Balances, shares at Dec. 31, 2022 |
|
|
45,796,449
|
|
|
|
|
Unrealized gain (loss) on investments |
976
|
|
|
|
|
|
|
Net income (loss) |
(90,355)
|
|
|
|
|
|
|
Balances at Jun. 30, 2023 |
499,574
|
|
$ 4
|
639,066
|
(1,625)
|
(137,871)
|
0
|
Balances, shares at Jun. 30, 2023 |
|
647,500
|
42,735,304
|
|
|
|
|
Balances at Mar. 31, 2023 |
485,649
|
|
$ 4
|
592,544
|
(1,242)
|
(105,657)
|
0
|
Balances, shares at Mar. 31, 2023 |
|
647,500
|
39,343,601
|
|
|
|
|
Net issuance of common stock under equity-based compensation plans |
(214)
|
|
|
(214)
|
|
|
|
Net issuance of common stock under equity-based compensation plans, shares |
|
|
81,703
|
|
|
|
|
Equity-based compensation |
7,920
|
|
|
7,920
|
|
|
|
Unrealized gain (loss) on investments |
(383)
|
|
|
|
(383)
|
|
|
Issuance of common stock |
38,388
|
|
|
38,388
|
|
|
|
Issuance of common stock, shares |
|
|
3,310,000
|
|
|
|
|
Net income (loss) |
(32,214)
|
|
|
|
|
(32,214)
|
|
Balances at Jun. 30, 2023 |
$ 499,574
|
|
$ 4
|
$ 639,066
|
$ (1,625)
|
$ (137,871)
|
$ 0
|
Balances, shares at Jun. 30, 2023 |
|
647,500
|
42,735,304
|
|
|
|
|
X |
- DefinitionIssuance of preferred stock in exchange for common stock
+ References
+ Details
Name: |
cgem_IssuanceOfPreferredStockInExchangeForCommonStock |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of preferred stock in exchange for common stock, Share
+ References
+ Details
Name: |
cgem_IssuanceOfPreferredStockInExchangeForCommonStockShare |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(2) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 23 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details
Name: |
us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884
Reference 23: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(1) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 31: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 23 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 105 -SubTopic 10 -Section 65 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 105 -SubTopic 10 -Section 65 -Paragraph 6 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (e)(3) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 5 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(2) -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 848 -SubTopic 10 -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 17 -URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(3) -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(1) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(1) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands |
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Operating activities: |
|
|
Net income (loss) |
$ (90,355)
|
$ 161,173
|
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
|
|
Equity-based compensation expense |
15,179
|
15,173
|
Amortization accretion on marketable securities |
(3,516)
|
1,737
|
Depreciation and amortization |
153
|
25
|
Non Cash Contributions From Noncontrolling Interests |
4
|
139
|
Gain on sale of Cullinan Pearl |
0
|
(276,785)
|
Realized loss on marketable securities |
0
|
109
|
Changes in operating assets and liabilities: |
|
|
Prepaid expenses and other current assets |
1,161
|
(1,050)
|
Accounts payable |
(169)
|
(70)
|
Accrued expenses and other current liabilities |
(178)
|
5,719
|
Income tax payable |
(4,282)
|
46,502
|
Net cash used in operating activities |
(82,003)
|
(47,328)
|
Investing activities: |
|
|
Proceeds from sales and maturities of marketable securities |
198,094
|
158,933
|
Purchase of marketable securities |
(170,592)
|
(93,370)
|
Purchase of property and equipment |
(208)
|
0
|
Proceeds from sale of Cullinan Pearl, net of escrow of $5,000 and cash transferred with sale of $2,898 |
0
|
270,000
|
Net cash provided by (used in) investing activities |
27,294
|
335,563
|
Financing activities: |
|
|
Proceeds from issuance of common stock |
38,388
|
0
|
Proceeds from issuance of convertible notes |
1,825
|
2,200
|
Proceeds from net issuance of common stock under equity-based compensation plans |
178
|
4,401
|
Repayment of convertible note |
0
|
(2,200)
|
Contributions From Noncontrolling Interests |
0
|
1,153
|
Net cash provided by financing activities |
40,391
|
5,554
|
Net increase (decrease) in cash and cash equivalents |
(14,318)
|
293,789
|
Cash and cash equivalents at beginning of period |
156,152
|
59,774
|
Cash and cash equivalents at end of period |
141,834
|
353,563
|
Non-cash financing activities and supplemental cash flow information |
|
|
Conversion Of Convertible Note Into Noncontrolling Interest |
175
|
0
|
Cash paid for income taxes |
$ 4,708
|
$ 0
|
X |
- DefinitionAmortization accretion on marketable securities.
+ References
+ Details
Name: |
cgem_AmortizationAccretionOnMarketableSecurities |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIncrease decrease in accrued expenses and other current liabilities.
+ References
+ Details
Name: |
cgem_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNon Cash Contributions From Noncontrolling Interests
+ References
+ Details
Name: |
cgem_NonCashContributionsFromNoncontrollingInterests |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from net issuance of common stock under equity-based compensation plans
+ References
+ Details
Name: |
cgem_ProceedsFromNetIssuanceOfCommonStockUnderEquityBasedCompensationPlans |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from sale of Cullinan Pearl, net of escrow
+ References
+ Details
Name: |
cgem_ProceedsFromSaleOfCullinanPearlNetOfEscrow |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
+ Details
Name: |
us-gaap_ConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(a)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(9)(a)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(7)(c)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details
Name: |
us-gaap_GainOnSaleOfInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).
+ References
+ Details
Name: |
us-gaap_MarketableSecuritiesRealizedGainLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 11 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562
+ Details
Name: |
us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from parent as a source of financing that is recorded as additional paid in capital.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromContributionsFromParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
+ Details
Name: |
us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884
Reference 23: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(1) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 31: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585
+ Details
Name: |
us-gaap_RepaymentsOfConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionCash transferred with sale.
+ References
+ Details
Name: |
cgem_CashTransferredWithSale |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfCashFlowsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Nature of Business and Basis of Presentation
|
6 Months Ended |
Jun. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Nature of Business and Basis of Presentation |
(1)Nature of Business and Basis of Presentation Organization Cullinan Oncology, Inc., together with its consolidated subsidiaries ("Cullinan" or the "Company"), is a clinical-stage biopharmaceutical company focused on modality-agnostic targeted oncology that was incorporated in September 2016 and has a principal place of business in Cambridge, Massachusetts. Liquidity The Company has incurred significant operating losses, with the exception of 2022, and negative cash flows from operations since its inception and expects to continue to generate operating losses for the foreseeable future. Cullinan’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company’s product candidates. Cullinan is subject to a number of risks including, but not limited to, the need to obtain adequate additional funding for the ongoing and planned clinical development of its product candidates. Due to the numerous risks and uncertainties associated with pharmaceutical products and development, the Company is unable to accurately predict the timing or amount of funds required to complete development of its product candidates, and costs could exceed Cullinan’s expectations for a number of reasons, including reasons beyond the Company’s control. Since inception, Cullinan has funded its operations primarily through the sale of equity securities and from licensing or selling the rights to its product candidates. The Company expects that its cash, cash equivalents and short-term investments of $491.8 million and long-term investments and interest receivable of $20.3 million as of June 30, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these unaudited consolidated financial statements. Interest receivable is included in prepaid expenses and other current assets on the consolidated balance sheets and represents accrued and unpaid interest on Cullinan's marketable securities.
|
X |
- DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI https://asc.fasb.org/topic&trid=2122369
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -URI https://asc.fasb.org/topic&trid=2122149
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI https://asc.fasb.org/topic&trid=2134479
+ Details
Name: |
us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Summary of Significant Accounting Policies
|
6 Months Ended |
Jun. 30, 2023 |
Accounting Policies [Abstract] |
|
Summary of Significant Accounting Policies |
(2)Summary of Significant Accounting Policies Cullinan’s significant accounting policies have not changed materially from those disclosed in its annual audited consolidated financial statements and accompanying notes in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 10-K”), except for its accounting policy for equity-based compensation. Basis of Presentation The unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") and in accordance with applicable rules and regulations of the Securities Exchange Commission (the "SEC") for interim financial reporting and include the accounts of the Company and its consolidated subsidiaries. Cullinan considers consolidation of entities over which control is achieved by means other than voting rights. Intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment, which is developing early-stage cancer therapeutics. In the opinion of Cullinan’s management, the unaudited consolidated financial statements reflect all adjustments, which are normal and recurring in nature, and necessary for fair financial statement presentation. The preparation of these unaudited consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These unaudited consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual audited consolidated financial statements and accompanying notes included in the 2022 10-K. Equity-Based Compensation The fair value of equity-based awards is measured at the grant date and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized as they occur. Cullinan classifies equity-based compensation in its consolidated statements of operations and comprehensive income (loss) in the same manner in which the award recipient’s payroll costs or service payments are classified. The fair value of service-based restricted stock units ("RSUs") is the closing market price of the Company's common stock on the grant date. Cullinan measures the fair value of market-based RSUs on the grant date using a Monte Carlo simulation model. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. Both the Monte Carlo simulation model and the Black-Scholes option pricing model require the input of objective and subjective assumptions. Certain assumptions used, including Cullinan's expected stock price volatility, involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, equity-based compensation expense could be materially different for future awards. Prior to 2023, the expected volatility used in the Black-Scholes option pricing model for new options was based on historical volatilities of the stock prices of similar entities within the Company’s industry over a period of time commensurate with the expected term assumption. In 2023, Cullinan determined that a sufficient amount of historical information was available regarding the volatility of its stock price to begin using a blended rate that combines the Company's historical volatility with the historical volatilities of the stock prices of similar entities within the Company’s industry over a period of time commensurate with the expected term assumption. Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that will have a material impact on Cullinan's consolidated financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI https://asc.fasb.org/topic&trid=2122369
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Sale of Cullinan Pearl and Co-Development Agreement with Taiho
|
6 Months Ended |
Jun. 30, 2023 |
Debt Securities, Available-for-Sale [Abstract] |
|
Sale of Cullinan Pearl and Co-Development Agreement with Taiho |
(3)Sale of Cullinan Pearl In June 2022, the Company sold its equity interest in its partially owned-subsidiary, Cullinan Pearl Corp. ("Cullinan Pearl"), which had worldwide rights to zipalertinib, excluding Japan, mainland China, Hong Kong, Macau, and Taiwan, to Taiho Pharmaceutical Co., Ltd ("Taiho") for an upfront payment of $275.0 million, with an increase to the purchase price in the amount of $2.9 million for cash held by Cullinan Pearl that was transferred with the sale. As of June 30, 2022, $5.0 million of the upfront payment was held in escrow. The escrow amount was released to Cullinan in the third quarter of 2022 once the Company and Taiho determined that no post-sale net working capital adjustment was necessary. Pursuant to the share purchase agreement with Taiho, Cullinan is also eligible to receive an additional $130.0 million tied to epidermal growth factor receptor exon20 non-small-cell lung cancer regulatory milestones. The Company concluded the transaction was a sale of non-financial assets, which were comprised mainly of intellectual property rights and related intangible assets, and that it transferred control of the non-financial assets at the closing of the sale. Cullinan recognized a gain on sale of Cullinan Pearl of $276.8 million within income from operations in its consolidated statement of operations and other comprehensive income (loss) for the three and six months ended June 30, 2022. The table below sets forth the book value of the Cullinan Pearl assets and liabilities sold along with the calculation of the gain on sale based on the cash consideration received.
|
|
|
|
|
|
|
(in thousands) |
|
Book value of assets sold |
|
|
|
Cash |
|
$ |
2,898 |
|
Prepaid expenses and other current assets |
|
|
619 |
|
Amounts attributable to assets sold |
|
|
3,517 |
|
Book value of liabilities sold |
|
|
|
Accrued expenses and other current liabilities |
|
|
2,404 |
|
Amounts attributable to liabilities sold |
|
|
2,404 |
|
Total identifiable net assets sold |
|
|
1,113 |
|
Upfront consideration, inclusive of escrow of $5,000 and cash transferred of $2,898 |
|
|
277,898 |
|
Gain on sale of Cullinan Pearl |
|
$ |
276,785 |
|
During the six months ended June 30, 2022, Cullinan Pearl issued $2.2 million of convertible notes to an affiliate of Taiho. The Company repaid these convertible notes at the closing of the Cullinan Pearl sale.
|
X |
- References
+ Details
Name: |
us-gaap_AvailableForSaleSecuritiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for sale leaseback transaction. Includes, but is not limited to, terms and conditions of transaction and gain (loss) from transaction.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 40 -URI https://asc.fasb.org/subtopic&trid=2209073
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 40 -URI https://asc.fasb.org/subtopic&trid=77888253
+ Details
Name: |
us-gaap_SaleLeasebackTransactionDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Financial Instruments
|
6 Months Ended |
Jun. 30, 2023 |
Financial Instruments Pledged as Collateral [Abstract] |
|
Financial Instruments |
Investments Cullinan recognized its short-term and long-term investments by security type at June 30, 2023 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
202,320 |
|
|
$ |
— |
|
|
$ |
(1,113 |
) |
|
$ |
201,207 |
|
U.S. government notes |
|
|
74,708 |
|
|
|
3 |
|
|
|
(86 |
) |
|
|
74,625 |
|
Asset-backed securities |
|
|
74,434 |
|
|
|
— |
|
|
|
(302 |
) |
|
|
74,132 |
|
Total short-term investments |
|
|
351,462 |
|
|
|
3 |
|
|
|
(1,501 |
) |
|
|
349,964 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
18,758 |
|
|
|
— |
|
|
|
(127 |
) |
|
|
18,631 |
|
Total long-term investments |
|
|
18,758 |
|
|
|
— |
|
|
|
(127 |
) |
|
|
18,631 |
|
Total investments |
|
$ |
370,220 |
|
|
$ |
3 |
|
|
$ |
(1,628 |
) |
|
$ |
368,595 |
|
The Company recognized its short-term and long-term investments by security type at December 31, 2022 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
244,498 |
|
|
$ |
11 |
|
|
$ |
(1,743 |
) |
|
$ |
242,766 |
|
U.S. government notes |
|
|
34,029 |
|
|
|
— |
|
|
|
(290 |
) |
|
|
33,739 |
|
Commercial paper |
|
|
18,035 |
|
|
|
3 |
|
|
|
(13 |
) |
|
|
18,025 |
|
Asset-backed securities |
|
|
16,625 |
|
|
|
— |
|
|
|
(15 |
) |
|
|
16,610 |
|
Total short-term investments |
|
|
313,187 |
|
|
|
14 |
|
|
|
(2,061 |
) |
|
|
311,140 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
81,436 |
|
|
|
18 |
|
|
|
(572 |
) |
|
|
80,882 |
|
Total long-term investments |
|
|
81,436 |
|
|
|
18 |
|
|
|
(572 |
) |
|
|
80,882 |
|
Total investments |
|
$ |
394,623 |
|
|
$ |
32 |
|
|
$ |
(2,633 |
) |
|
$ |
392,022 |
|
Fair Value of Financial Instruments The following table sets forth the fair value of Cullinan’s financial assets that were measured at fair value on a recurring basis as of June 30, 2023:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
— |
|
|
$ |
201,207 |
|
|
$ |
— |
|
|
$ |
201,207 |
|
U.S. government notes |
|
|
— |
|
|
|
74,625 |
|
|
|
— |
|
|
|
74,625 |
|
Asset-backed securities |
|
|
— |
|
|
|
74,132 |
|
|
|
— |
|
|
|
74,132 |
|
Total short-term investments |
|
|
— |
|
|
|
349,964 |
|
|
|
— |
|
|
|
349,964 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
— |
|
|
|
18,631 |
|
|
|
— |
|
|
|
18,631 |
|
Total long-term investments |
|
|
— |
|
|
|
18,631 |
|
|
|
— |
|
|
|
18,631 |
|
Total investments |
|
$ |
— |
|
|
$ |
368,595 |
|
|
$ |
— |
|
|
$ |
368,595 |
|
The following table sets forth the fair value of the Company’s financial assets that were measured at fair value on a recurring basis as of December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
— |
|
|
$ |
242,766 |
|
|
$ |
— |
|
|
$ |
242,766 |
|
U.S. government notes |
|
|
— |
|
|
|
33,739 |
|
|
|
— |
|
|
|
33,739 |
|
Commercial paper |
|
|
— |
|
|
|
18,025 |
|
|
|
— |
|
|
|
18,025 |
|
Asset-backed securities |
|
|
— |
|
|
|
16,610 |
|
|
|
— |
|
|
|
16,610 |
|
Total short-term investments |
|
|
— |
|
|
|
311,140 |
|
|
|
— |
|
|
|
311,140 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
— |
|
|
|
80,882 |
|
|
|
— |
|
|
|
80,882 |
|
Total long-term investments |
|
|
— |
|
|
|
80,882 |
|
|
|
— |
|
|
|
80,882 |
|
Total investments |
|
$ |
— |
|
|
$ |
392,022 |
|
|
$ |
— |
|
|
$ |
392,022 |
|
As of June 30, 2023 and December 31, 2022, the fair values of Cullinan's cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximated their carrying values due to the short-term nature of these instruments.
|
X |
- DefinitionThe entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.
+ References
+ Details
Name: |
us-gaap_FinancialInstrumentsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FinancialInstrumentsPledgedAsCollateralAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Accrued Expenses and Other Current Liabilities
|
6 Months Ended |
Jun. 30, 2023 |
Accrued Expenses And Other Current Liabilities [Abstract] |
|
Accrued Expenses and Other Current Liabilities |
(5)Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of June 30, 2023 and December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
|
|
(in thousands) |
|
Accrued research and development expenses |
|
$ |
6,130 |
|
|
$ |
7,486 |
|
Due to Taiho under collaboration agreement, net |
|
|
3,378 |
|
|
|
— |
|
Accrued bonus |
|
|
3,108 |
|
|
|
4,516 |
|
Convertible note and accrued interest |
|
|
1,885 |
|
|
|
178 |
|
Other current liabilities |
|
|
1,030 |
|
|
|
1,955 |
|
Total accrued expenses and other current liabilities |
|
$ |
15,531 |
|
|
$ |
14,135 |
|
|
X |
- DefinitionAccrued expenses and other current liabilities.
+ References
+ Details
Name: |
cgem_AccruedExpensesAndOtherCurrentLiabilitiesAbstract |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
License and Collaboration Agreements
|
6 Months Ended |
Jun. 30, 2023 |
License And Collaboration Agreements [Abstract] |
|
License and Collaboration Agreements |
(6)License and Collaboration Agreements Harbour License Agreement In February 2023, the Company and Harbour BioMed US Inc. (“Harbour”) entered into a license and collaboration agreement (the “Harbour License Agreement”), pursuant to which Harbour granted to Cullinan an exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S. Under the terms of the Harbour License Agreement, the Company paid Harbour an upfront license fee of $25.0 million at signing. Harbour will be eligible to receive up to $148.0 million in milestone payments based on the achievement of pre-specified development and regulatory milestones. Harbour is also eligible to receive up to an additional $415.0 million in sales-based milestones as well as tiered royalties up to the high teens on a licensed product-by-licensed product basis, as a percentage of U.S. commercial sales. In addition, under the Harbour License Agreement, Harbour granted Cullinan certain intellectual property rights to enable the Company to perform its obligations and exercise its rights under the Harbour License Agreement. Unless earlier terminated, the Harbour License Agreement will continue in effect until the expiration of Cullinan’s royalty obligations. The Harbour License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party’s insolvency. The Company may terminate the Harbour License Agreement for convenience by providing 90 days written notice to Harbour. In the Harbour License Agreement, each party made customary representations and warranties and agreed to customary covenants, including, without limitation, with respect to indemnification, for transactions of this type. Cullinan evaluated the Harbour License Agreement and determined that the exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S represented an asset acquisition of in-process research and development. The Company also determined that the asset had no alternative future use at the time of acquisition, and therefore the upfront license fee of $25.0 million was recorded within research and development expenses during the six months ended June 30, 2023. Co-Development Agreement with Taiho In June 2022, Cullinan and an affiliate of Taiho entered into a co-development agreement, pursuant to which the Company will collaborate to develop zipalertinib and will retain the option to co-commercialize zipalertinib in the U.S. Under the co-development agreement, development costs for zipalertinib shall be shared equally between Taiho and Cullinan with each party receiving 50% of any future pre-tax profits from potential U.S. sales of zipalertinib. The Company concluded that the co-development agreement with Taiho is a collaborative arrangement because Cullinan is an active participant in the development of zipalertinib. Payments made to or received from Taiho for zipalertinib development activities after the execution of the co-development agreement are recorded within research and development expenses. For the three and six months ended June 30, 2023, the Company recorded research and development expense of $5.5 million and $10.2 million, respectively, related to its share of costs incurred by Taiho. Cullinan incurred $2.1 million and $3.1 million of costs that were reimbursable by Taiho during the three and six months ended June 30, 2023, respectively, which were recorded as a reduction to research and development expenses. The net amount of $3.4 million due to Taiho was recorded within accrued expenses and other current liabilities as of June 30, 2023. Other License and Collaboration Expenses During the six months ended June 30, 2023, Cullinan recorded $0.2 million in research and development expenses relating to the license agreement with the Massachusetts Institute of Technology (the "MIT License Agreement") for CLN-617. During the three and six months ended June 30, 2022, the Company recorded $0.2 million in research and development expenses relating to the MIT License Agreement. During the six months ended June 30, 2022, Cullinan recorded $0.5 million in research and development expenses relating to a collaboration agreement with Adimab, LLC.
|
X |
- DefinitionLicense and collaboration agreements.
+ References
+ Details
Name: |
cgem_LicenseAndCollaborationAgreementsAbstract |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLicense and collaboration agreements.
+ References
+ Details
Name: |
cgem_LicenseAndCollaborationAgreementsTextBlock |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Stockholders' Equity
|
6 Months Ended |
Jun. 30, 2023 |
Stockholders' Equity Note [Abstract] |
|
Stockholders' Equity |
Common Stock Each share of common stock entitles the holder to one vote and to receive dividends when and if declared by the board of directors of the Company. No dividends have been declared through June 30, 2023. At-the-Market Equity Offering Program In May 2023, Cullinan entered into an agreement with Cowen and Company, LLC (“Cowen”) to establish an at-the-market equity offering program (the “ATM") pursuant to which the Company may offer and sell up to $125.0 million of its common stock from time to time through Cowen, acting as its sales agent. In the three months ended June 30, 2023, the Company sold approximately 3.3 million shares under the ATM and received net proceeds of $38.4 million after deducting commissions. As of June 30, 2023, Cullinan had $85.6 million in shares of its common stock remaining under the ATM. Preferred Stock In January 2023, the Company entered into an exchange agreement with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (the “Stockholders”), pursuant to which the Stockholders exchanged 6.5 million shares of Cullinan’s common stock for 0.6 million shares of newly designated Series A convertible preferred stock, a “toothless” preferred stock, par value $0.0001 per share. Each share of the preferred stock will be convertible into ten shares of common stock at the option of the holder at any time, subject to certain limitations, including that the holder will be prohibited from converting preferred stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock more than 9.99% of the total common stock then issued and outstanding immediately following the conversion of such shares of preferred stock. Holders of the preferred stock are permitted to increase this percentage to an amount not to exceed 19.99% upon 60 days notice. Shares of preferred stock will generally have no voting rights, except as required by law and except that the consent of a majority of the holders of the outstanding preferred stock will be required to amend the terms of the preferred stock. In the event of the Company’s liquidation, dissolution or winding up, holders of preferred stock will participate pari passu with any distribution of proceeds to holders of common stock. Holders of preferred stock are entitled to receive when, as, and if dividends are declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of preferred stock are otherwise not entitled to dividends. The preferred stock ranks (i) senior to any class or series of capital stock of Cullinan hereafter created specifically ranking by its terms junior to the preferred stock; (ii) on parity with the common stock and any class or series of capital stock of the Company created specifically ranking by its terms on parity with the preferred stock; and (iii) junior to any class or series of capital stock of Cullinan created specifically ranking by its terms senior to any preferred stock, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily. The Company evaluated the preferred stock for liability or equity classification. Cullinan determined that the preferred stock should be classified as permanent equity as it is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company. Noncontrolling Interests in Subsidiaries Certain subsidiaries issue common stock in connection with licensing agreements and to employees, directors and consultants pursuant to subsidiary equity incentive plans. The holders of subsidiary common stock are entitled to one vote per share. The holders of subsidiary common stock are entitled to receive dividends when and if declared by the subsidiaries’ board of directors and distributions in either case only after the payment of all preferential amounts required to be paid to the holders of shares of preferred stock of the respective subsidiary. Cullinan Amber As of June 30, 2023, the Company held common stock and Series A preferred stock that represented 94% of Cullinan Amber Corp.’s ("Cullinan Amber") outstanding equity. As of June 30, 2023, noncontrolling interests collectively held common stock that represented 6% of Cullinan Amber's outstanding equity. In each of the three and six months ended June 30, 2023, no losses were attributed to the noncontrolling interests of Cullinan Amber. In each of the three and six months ended June 30, 2022, $0.1 million of losses were attributed to the noncontrolling interests of Cullinan Amber. Cullinan Florentine As of June 30, 2023, Cullinan held common stock, Series A preferred stock and Series B preferred stock that represented 96% of Cullinan Florentine Corp.'s ("Cullinan Florentine") outstanding equity. As of June 30, 2023, noncontrolling interests collectively held common stock that represented 4% of Cullinan Florentine's outstanding equity. In each of the three and six months ended June 30, 2023 and 2022, no losses were attributed to the noncontrolling interests of Cullinan Florentine. Cullinan MICA As of June 30, 2023, Cullinan held common stock and Series A preferred stock that represented 96% of Cullinan MICA Corp.'s ("Cullinan MICA") outstanding equity. As of June 30, 2023, noncontrolling interests collectively held common stock and Series A preferred stock that represented 4% of Cullinan MICA's outstanding equity. In the three and six months ended June 30, 2023, no losses and $0.2 million of losses, respectively, were attributed to the noncontrolling interests of Cullinan MICA. In the three and six months ended June 30, 2022, $0.7 million and $1.1 million of losses, respectively, were attributed to the noncontrolling interests of Cullinan MICA. Cullinan Pearl In June 2022, the Company sold its equity interest in its partially-owned subsidiary, Cullinan Pearl, to Taiho. Refer to Note 3 for additional details relating to the transaction. In the three and six months ended June 30, 2022, no losses and $0.3 million of losses, respectively, were attributed to the noncontrolling interests of Cullinan Pearl.
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityNoteAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Equity-Based Compensation
|
6 Months Ended |
Jun. 30, 2023 |
Share-Based Payment Arrangement [Abstract] |
|
Equity-Based Compensation |
(8)Equity-Based Compensation Cullinan recorded equity-based compensation in the following expense categories in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Research and development |
|
$ |
3,249 |
|
|
$ |
4,379 |
|
|
$ |
6,303 |
|
|
$ |
7,039 |
|
General and administrative |
|
|
4,671 |
|
|
|
4,229 |
|
|
|
8,876 |
|
|
|
8,134 |
|
Total equity-based compensation |
|
$ |
7,920 |
|
|
$ |
8,608 |
|
|
$ |
15,179 |
|
|
$ |
15,173 |
|
Determining Fair Value of Options The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the value of the underlying common stock at the grant date, expected term, expected volatility, risk-free interest rate and dividend yield. The fair value of each grant of options during the six months ended June 30, 2023 and 2022 were determined using the methods and assumptions discussed below: •The expected term of options is determined using the “simplified” method, as prescribed in the SEC Staff Accounting Bulletin No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data. •The risk-free interest rate is based on implied yields available from U.S. Treasury securities with a remaining term equal to the expected term assumed at the grant date. •Prior to 2023, the expected volatility used in the Black-Scholes option pricing model for new options was based on historical volatilities of the stock prices of similar entities within Cullinan’s industry over a period of time commensurate with the expected term assumption. In 2023, the Company determined that a sufficient amount of historical information was available regarding the volatility of its stock price to begin using a blended rate that combines its historical volatility with the historical volatilities of the stock prices of similar entities within Cullinan’s industry over a period of time commensurate with the expected term assumption. •The estimated annual dividend yield was based on the Company’s expectation of not paying dividends on its common stock in the foreseeable future. The grant date fair value was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted-average assumptions in the six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
2023 |
|
2022 |
Risk-free interest rate |
|
3.9% |
|
2.2% |
Expected term (in years) |
|
6.0 |
|
6.0 |
Expected volatility |
|
79.1% |
|
78.8% |
Expected dividend yield |
|
0.0% |
|
0.0% |
|
X |
- DefinitionThe entire disclosure for share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Related Party Transactions
|
6 Months Ended |
Jun. 30, 2023 |
Related Party Transactions [Abstract] |
|
Related Party Transactions |
(9)Related Party Transactions Royalty Transfer Agreements Cullinan Amber, Cullinan Florentine and Cullinan MICA are each party to royalty transfer agreements with MPM Oncology Charitable Foundation, Inc. and UBS Optimus Foundation (together, the "Foundations"). Under each of these respective agreements, the Foundations are collectively entitled to receive a low single digit royalty percentage of all global net sales of any products developed by the applicable subsidiary, subject to limitations after patent expirations and on intellectual property developed after a change of control. Cullinan has deemed these royalty transfer agreements to be freestanding financial instruments that should be accounted for at fair value. The Company concluded that these instruments had no value at the inception of the agreements. Cullinan has not had any applicable net sales from its products and as a result, has not paid or incurred any royalties under these agreements as of June 30, 2023. Given the early-stage nature of the underlying technologies and inherent technical, regulatory and competitive risks associated with achieving approval and commercialization, the Company ascribed no value to the royalty transfer agreements as of June 30, 2023 and December 31, 2022.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI https://asc.fasb.org/topic&trid=2122745
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Income Taxes
|
6 Months Ended |
Jun. 30, 2023 |
Income Tax Disclosure [Abstract] |
|
Income Taxes |
During each of the three and six months ended June 30, 2023, Cullinan did not record an income tax expense or benefit. During the three and six months ended June 30, 2022, the Company recorded an income tax provision of $66.1 million and $46.5 million, respectively. The tax provision recorded for the period ended June 30, 2022 was driven by the expected tax from the gain on sale of Cullinan Pearl, partially offset by the release of valuation allowance for the expected utilization of certain historical tax attributes against the gain from the sale. Refer to Note 3 for additional details on the sale of Cullinan's equity interest in Cullinan Pearl. The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of capitalized research and development costs, temporary differences on equity-based compensation, and net operating loss carryforwards. Cullinan has considered its history of cumulative net losses and its estimated future taxable income and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, Cullinan has maintained a full valuation allowance against its remaining net deferred tax assets as of June 30, 2023.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 270 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -URI https://asc.fasb.org/topic&trid=2144680
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Commitments and Contingencies
|
6 Months Ended |
Jun. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
Commitments and Contingencies |
(11)Commitments and Contingencies The Company enters into contracts in the normal course of business with contract research organizations, contract manufacturing organizations, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These agreements generally include cancellation clauses. Indemnification Agreements In the ordinary course of business, Cullinan may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require Cullinan, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in certain cases, unlimited. To date, Cullinan has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2023 and December 31, 2022. Legal Proceedings Cullinan is not currently party to or aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. Cullinan expenses as incurred the costs related to such legal proceedings.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -URI https://asc.fasb.org/topic&trid=2144648
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 440 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -URI https://asc.fasb.org/topic&trid=2127136
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Leases
|
6 Months Ended |
Jun. 30, 2023 |
Leases [Abstract] |
|
Leases |
The Company has an operating lease for approximately 8,000 square feet of office space in a multi-tenant building in Cambridge, Massachusetts, which commenced in February 2018 and goes through June 2024 (the "Suite 520 Lease"). In August 2022, Cullinan entered into an additional operating lease for approximately 14,000 square feet of office space in a multi-tenant building in Cambridge, Massachusetts through July 2026. Lease expense consisted of operating lease costs of $0.4 million and $0.9 million for the three and six months ended June 30, 2023, respectively. Lease expense consisted of operating lease costs of $0.1 million and $0.3 million for the three and six months ended June 30, 2022, respectively. The following table summarizes supplemental cash flow information for the six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Cash paid for amounts included in measurement of lease liabilities: |
|
|
|
|
|
|
Operating cash flows from operating leases |
|
$ |
875 |
|
|
$ |
303 |
|
Right-of-use asset obtained in exchange for an operating lease liability |
|
$ |
— |
|
|
$ |
1,311 |
|
The following table summarizes the Company’s future minimum lease payments and reconciliation of lease liabilities as of June 30, 2023:
|
|
|
|
|
|
|
June 30, 2023 |
|
|
|
(in thousands) |
|
Remainder of 2023 |
|
$ |
1,006 |
|
2024 |
|
|
1,738 |
|
2025 |
|
|
1,461 |
|
2026 |
|
|
872 |
|
Total future minimum lease payments |
|
|
5,077 |
|
Less: imputed interest |
|
|
(691 |
) |
Total lease liabilities at present value |
|
$ |
4,386 |
|
The following table summarizes the weighted-average remaining lease term and discount rate as of June 30, 2023 and December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
Weighted-average remaining lease term (in years) |
|
|
2.8 |
|
|
|
3.2 |
|
Weighted-average discount rate |
|
|
10.8 |
% |
|
|
10.8 |
% |
As Cullinan’s operating leases did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available in determining the present value of lease payments. Cullinan’s incremental borrowing rate was based on the term of the lease, the economic environment and reflects the rate the Company would have had to pay to borrow on a secured basis. Sublease Agreement In September 2022, Cullinan entered into a sublease agreement through May 2024 for the Suite 520 Lease. For the three and six months ended June 30, 2023, the Company recorded sublease income of $0.1 million and $0.3 million, respectively, within other income (expense), net.
|
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -URI https://asc.fasb.org/subtopic&trid=77888251
+ Details
Name: |
us-gaap_LesseeOperatingLeasesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Net Income (Loss) per Share
|
6 Months Ended |
Jun. 30, 2023 |
Earnings Per Share [Abstract] |
|
Net Income (Loss) per Share |
(13)Net Income (Loss) per Share The following table sets forth the calculation of basic and diluted net income (loss) per share for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands, except per share data) |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders of Cullinan |
|
$ |
(32,214 |
) |
|
$ |
174,898 |
|
|
$ |
(90,176 |
) |
|
$ |
162,800 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common stock outstanding - basic |
|
|
39,952 |
|
|
|
44,873 |
|
|
|
40,315 |
|
|
|
44,654 |
|
Dilutive effect of common stock issuable from assumed exercise of equity awards |
|
|
— |
|
|
|
1,508 |
|
|
|
— |
|
|
|
1,735 |
|
Weighted-average common stock outstanding - diluted |
|
|
39,952 |
|
|
|
46,381 |
|
|
|
40,315 |
|
|
|
46,389 |
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.82 |
) |
|
$ |
3.90 |
|
|
$ |
(2.24 |
) |
|
$ |
3.65 |
|
Diluted |
|
$ |
(0.82 |
) |
|
$ |
3.77 |
|
|
$ |
(2.24 |
) |
|
$ |
3.51 |
|
Cullinan used the treasury stock and if-converted methods to determine the number of dilutive shares. The following table sets forth potential common shares that were excluded from the computation of diluted net income (loss) per share for the six months ended June 30, 2023 and 2022 because their effect would have been anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Stock options |
|
|
9,185 |
|
|
|
6,250 |
|
Preferred stock |
|
|
5,795 |
|
|
|
— |
|
Restricted stock awards and RSUs |
|
|
156 |
|
|
|
— |
|
Total |
|
|
15,136 |
|
|
|
6,250 |
|
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for earnings per share.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257
+ Details
Name: |
us-gaap_EarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Summary of Significant Accounting Policies (Policies)
|
6 Months Ended |
Jun. 30, 2023 |
Accounting Policies [Abstract] |
|
Basis of Presentation |
Basis of Presentation The unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") and in accordance with applicable rules and regulations of the Securities Exchange Commission (the "SEC") for interim financial reporting and include the accounts of the Company and its consolidated subsidiaries. Cullinan considers consolidation of entities over which control is achieved by means other than voting rights. Intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment, which is developing early-stage cancer therapeutics. In the opinion of Cullinan’s management, the unaudited consolidated financial statements reflect all adjustments, which are normal and recurring in nature, and necessary for fair financial statement presentation. The preparation of these unaudited consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These unaudited consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual audited consolidated financial statements and accompanying notes included in the 2022 10-K.
|
Equity-based Compensation |
Equity-Based Compensation The fair value of equity-based awards is measured at the grant date and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized as they occur. Cullinan classifies equity-based compensation in its consolidated statements of operations and comprehensive income (loss) in the same manner in which the award recipient’s payroll costs or service payments are classified. The fair value of service-based restricted stock units ("RSUs") is the closing market price of the Company's common stock on the grant date. Cullinan measures the fair value of market-based RSUs on the grant date using a Monte Carlo simulation model. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. Both the Monte Carlo simulation model and the Black-Scholes option pricing model require the input of objective and subjective assumptions. Certain assumptions used, including Cullinan's expected stock price volatility, involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, equity-based compensation expense could be materially different for future awards. Prior to 2023, the expected volatility used in the Black-Scholes option pricing model for new options was based on historical volatilities of the stock prices of similar entities within the Company’s industry over a period of time commensurate with the expected term assumption. In 2023, Cullinan determined that a sufficient amount of historical information was available regarding the volatility of its stock price to begin using a blended rate that combines the Company's historical volatility with the historical volatilities of the stock prices of similar entities within the Company’s industry over a period of time commensurate with the expected term assumption.
|
Recently Adopted Accounting Pronouncements |
Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that will have a material impact on Cullinan's consolidated financial statements.
|
X |
- DefinitionRecently adopted accounting pronouncements.
+ References
+ Details
Name: |
cgem_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -URI https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Sale of Cullinan Pearl and Co-Development Agreement with Taiho (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Debt Securities, Available-for-Sale [Abstract] |
|
Schedule of cash consideration received |
|
|
|
|
|
|
|
(in thousands) |
|
Book value of assets sold |
|
|
|
Cash |
|
$ |
2,898 |
|
Prepaid expenses and other current assets |
|
|
619 |
|
Amounts attributable to assets sold |
|
|
3,517 |
|
Book value of liabilities sold |
|
|
|
Accrued expenses and other current liabilities |
|
|
2,404 |
|
Amounts attributable to liabilities sold |
|
|
2,404 |
|
Total identifiable net assets sold |
|
|
1,113 |
|
Upfront consideration, inclusive of escrow of $5,000 and cash transferred of $2,898 |
|
|
277,898 |
|
Gain on sale of Cullinan Pearl |
|
$ |
276,785 |
|
|
X |
- DefinitionSchedule of Cash Consideration Received Table Text Block
+ References
+ Details
Name: |
cgem_ScheduleOfCashConsiderationReceivedTableTextBlock |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AvailableForSaleSecuritiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Financial Instruments (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Financial Instruments Pledged as Collateral [Abstract] |
|
Schedule of Short-term and Long-term Investment Marketable Securities by Security Type |
Investments Cullinan recognized its short-term and long-term investments by security type at June 30, 2023 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
202,320 |
|
|
$ |
— |
|
|
$ |
(1,113 |
) |
|
$ |
201,207 |
|
U.S. government notes |
|
|
74,708 |
|
|
|
3 |
|
|
|
(86 |
) |
|
|
74,625 |
|
Asset-backed securities |
|
|
74,434 |
|
|
|
— |
|
|
|
(302 |
) |
|
|
74,132 |
|
Total short-term investments |
|
|
351,462 |
|
|
|
3 |
|
|
|
(1,501 |
) |
|
|
349,964 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
18,758 |
|
|
|
— |
|
|
|
(127 |
) |
|
|
18,631 |
|
Total long-term investments |
|
|
18,758 |
|
|
|
— |
|
|
|
(127 |
) |
|
|
18,631 |
|
Total investments |
|
$ |
370,220 |
|
|
$ |
3 |
|
|
$ |
(1,628 |
) |
|
$ |
368,595 |
|
The Company recognized its short-term and long-term investments by security type at December 31, 2022 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized Cost |
|
|
Gross Unrealized Gains |
|
|
Gross Unrealized Losses |
|
|
Estimated Fair Value |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
244,498 |
|
|
$ |
11 |
|
|
$ |
(1,743 |
) |
|
$ |
242,766 |
|
U.S. government notes |
|
|
34,029 |
|
|
|
— |
|
|
|
(290 |
) |
|
|
33,739 |
|
Commercial paper |
|
|
18,035 |
|
|
|
3 |
|
|
|
(13 |
) |
|
|
18,025 |
|
Asset-backed securities |
|
|
16,625 |
|
|
|
— |
|
|
|
(15 |
) |
|
|
16,610 |
|
Total short-term investments |
|
|
313,187 |
|
|
|
14 |
|
|
|
(2,061 |
) |
|
|
311,140 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
81,436 |
|
|
|
18 |
|
|
|
(572 |
) |
|
|
80,882 |
|
Total long-term investments |
|
|
81,436 |
|
|
|
18 |
|
|
|
(572 |
) |
|
|
80,882 |
|
Total investments |
|
$ |
394,623 |
|
|
$ |
32 |
|
|
$ |
(2,633 |
) |
|
$ |
392,022 |
|
|
Summary of Fair Value of Financial Assets Measured at Fair Value on a Recurring Basis |
The following table sets forth the fair value of Cullinan’s financial assets that were measured at fair value on a recurring basis as of June 30, 2023:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
— |
|
|
$ |
201,207 |
|
|
$ |
— |
|
|
$ |
201,207 |
|
U.S. government notes |
|
|
— |
|
|
|
74,625 |
|
|
|
— |
|
|
|
74,625 |
|
Asset-backed securities |
|
|
— |
|
|
|
74,132 |
|
|
|
— |
|
|
|
74,132 |
|
Total short-term investments |
|
|
— |
|
|
|
349,964 |
|
|
|
— |
|
|
|
349,964 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
— |
|
|
|
18,631 |
|
|
|
— |
|
|
|
18,631 |
|
Total long-term investments |
|
|
— |
|
|
|
18,631 |
|
|
|
— |
|
|
|
18,631 |
|
Total investments |
|
$ |
— |
|
|
$ |
368,595 |
|
|
$ |
— |
|
|
$ |
368,595 |
|
The following table sets forth the fair value of the Company’s financial assets that were measured at fair value on a recurring basis as of December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
|
(in thousands) |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
$ |
— |
|
|
$ |
242,766 |
|
|
$ |
— |
|
|
$ |
242,766 |
|
U.S. government notes |
|
|
— |
|
|
|
33,739 |
|
|
|
— |
|
|
|
33,739 |
|
Commercial paper |
|
|
— |
|
|
|
18,025 |
|
|
|
— |
|
|
|
18,025 |
|
Asset-backed securities |
|
|
— |
|
|
|
16,610 |
|
|
|
— |
|
|
|
16,610 |
|
Total short-term investments |
|
|
— |
|
|
|
311,140 |
|
|
|
— |
|
|
|
311,140 |
|
Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
Corporate notes |
|
|
— |
|
|
|
80,882 |
|
|
|
— |
|
|
|
80,882 |
|
Total long-term investments |
|
|
— |
|
|
|
80,882 |
|
|
|
— |
|
|
|
80,882 |
|
Total investments |
|
$ |
— |
|
|
$ |
392,022 |
|
|
$ |
— |
|
|
$ |
392,022 |
|
As of June 30, 2023 and December 31, 2022, the fair values of Cullinan's cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximated their carrying values due to the short-term nature of these instruments.
|
X |
- DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI https://asc.fasb.org/topic&trid=2196928
+ Details
Name: |
us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2C -URI https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bb) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FinancialInstrumentsPledgedAsCollateralAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Accrued Expenses and Other Current Liabilities (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Accrued Expenses And Other Current Liabilities [Abstract] |
|
Summary of Accrued Expenses and Other Current Liabilities |
Accrued expenses and other current liabilities consisted of the following as of June 30, 2023 and December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
|
|
(in thousands) |
|
Accrued research and development expenses |
|
$ |
6,130 |
|
|
$ |
7,486 |
|
Due to Taiho under collaboration agreement, net |
|
|
3,378 |
|
|
|
— |
|
Accrued bonus |
|
|
3,108 |
|
|
|
4,516 |
|
Convertible note and accrued interest |
|
|
1,885 |
|
|
|
178 |
|
Other current liabilities |
|
|
1,030 |
|
|
|
1,955 |
|
Total accrued expenses and other current liabilities |
|
$ |
15,531 |
|
|
$ |
14,135 |
|
|
X |
- DefinitionAccrued expenses and other current liabilities.
+ References
+ Details
Name: |
cgem_AccruedExpensesAndOtherCurrentLiabilitiesAbstract |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe disclosure of accrued expenses and other current liabilities.
+ References
+ Details
Name: |
cgem_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Equity-Based Compensation (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Share-Based Payment Arrangement [Abstract] |
|
Schedule of Equity-based Compensation Expense Categories In Consolidated Statements of Operations and Comprehensive Income (Loss) |
Cullinan recorded equity-based compensation in the following expense categories in the consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Research and development |
|
$ |
3,249 |
|
|
$ |
4,379 |
|
|
$ |
6,303 |
|
|
$ |
7,039 |
|
General and administrative |
|
|
4,671 |
|
|
|
4,229 |
|
|
|
8,876 |
|
|
|
8,134 |
|
Total equity-based compensation |
|
$ |
7,920 |
|
|
$ |
8,608 |
|
|
$ |
15,179 |
|
|
$ |
15,173 |
|
|
Schedule of Assumptions Used to Estimate Fair value of Market-Based RSUs Granted |
The grant date fair value was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted-average assumptions in the six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
2023 |
|
2022 |
Risk-free interest rate |
|
3.9% |
|
2.2% |
Expected term (in years) |
|
6.0 |
|
6.0 |
Expected volatility |
|
79.1% |
|
78.8% |
Expected dividend yield |
|
0.0% |
|
0.0% |
|
X |
- DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Leases (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Leases [Abstract] |
|
Supplemental Cash Flow Information Relating to Leases |
The following table summarizes supplemental cash flow information for the six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Cash paid for amounts included in measurement of lease liabilities: |
|
|
|
|
|
|
Operating cash flows from operating leases |
|
$ |
875 |
|
|
$ |
303 |
|
Right-of-use asset obtained in exchange for an operating lease liability |
|
$ |
— |
|
|
$ |
1,311 |
|
|
Summarizes of future minimum lease payments |
The following table summarizes the Company’s future minimum lease payments and reconciliation of lease liabilities as of June 30, 2023:
|
|
|
|
|
|
|
June 30, 2023 |
|
|
|
(in thousands) |
|
Remainder of 2023 |
|
$ |
1,006 |
|
2024 |
|
|
1,738 |
|
2025 |
|
|
1,461 |
|
2026 |
|
|
872 |
|
Total future minimum lease payments |
|
|
5,077 |
|
Less: imputed interest |
|
|
(691 |
) |
Total lease liabilities at present value |
|
$ |
4,386 |
|
|
Summarizes Lease Term and Discount Rate |
The following table summarizes the weighted-average remaining lease term and discount rate as of June 30, 2023 and December 31, 2022:
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
Weighted-average remaining lease term (in years) |
|
|
2.8 |
|
|
|
3.2 |
|
Weighted-average discount rate |
|
|
10.8 |
% |
|
|
10.8 |
% |
|
X |
- DefinitionSummarizes Lease Term and Discount Rate Table Text Block
+ References
+ Details
Name: |
cgem_SummarizesLeaseTermAndDiscountRateTableTextBlock |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities.
+ References
+ Details
Name: |
us-gaap_CashFlowOperatingCapitalTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Net Income (Loss) per Share (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Earnings Per Share [Abstract] |
|
Summary of Calculation of Basic and Diluted Net Loss Per Share |
The following table sets forth the calculation of basic and diluted net income (loss) per share for the three and six months ended June 30, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands, except per share data) |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders of Cullinan |
|
$ |
(32,214 |
) |
|
$ |
174,898 |
|
|
$ |
(90,176 |
) |
|
$ |
162,800 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common stock outstanding - basic |
|
|
39,952 |
|
|
|
44,873 |
|
|
|
40,315 |
|
|
|
44,654 |
|
Dilutive effect of common stock issuable from assumed exercise of equity awards |
|
|
— |
|
|
|
1,508 |
|
|
|
— |
|
|
|
1,735 |
|
Weighted-average common stock outstanding - diluted |
|
|
39,952 |
|
|
|
46,381 |
|
|
|
40,315 |
|
|
|
46,389 |
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.82 |
) |
|
$ |
3.90 |
|
|
$ |
(2.24 |
) |
|
$ |
3.65 |
|
Diluted |
|
$ |
(0.82 |
) |
|
$ |
3.77 |
|
|
$ |
(2.24 |
) |
|
$ |
3.51 |
|
|
Summary of Outstanding Equity Instruments Excluded from Computation of Diluted Net Income (Loss) Per Share |
The following table sets forth potential common shares that were excluded from the computation of diluted net income (loss) per share for the six months ended June 30, 2023 and 2022 because their effect would have been anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(in thousands) |
|
Stock options |
|
|
9,185 |
|
|
|
6,250 |
|
Preferred stock |
|
|
5,795 |
|
|
|
— |
|
Restricted stock awards and RSUs |
|
|
156 |
|
|
|
— |
|
Total |
|
|
15,136 |
|
|
|
6,250 |
|
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details
Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionCash, cash equivalents, short-term investments and long-term investments.
+ References
+ Details
Name: |
cgem_CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNature of business and basis of presentation.
+ References
+ Details
Name: |
cgem_NatureOfBusinessAndBasisOfPresentationLineItems |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of long-term investments classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.1(f)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_OtherLongTermInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599
+ Details
Name: |
us-gaap_NumberOfOperatingSegments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
Reorganization and Reverse Stock Split - Summary of LLC Units Previously Reported as Redeemable Preferred Units or Temporary Equity Converted Reclassified to Equity (Details) - USD ($) $ in Thousands |
Jun. 30, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Dec. 31, 2021 |
Stockholders' Equity (Members' Deficit) |
|
|
|
|
|
|
Common Stock |
$ 4
|
|
$ 5
|
|
|
|
Additional paid-in capital |
639,066
|
|
585,320
|
|
|
|
Accumulated other comprehensive loss |
(1,625)
|
|
(2,601)
|
|
|
|
Accumulated deficit |
(137,871)
|
|
(47,695)
|
|
|
|
Total Cullinan Stockholders' Equity (Members' Deficit) |
499,574
|
|
535,029
|
|
|
|
Non-controlling interests in subsidiaries |
0
|
|
0
|
|
|
|
Total Stockholders' Equity (Members' Deficit) |
$ 499,574
|
$ 485,649
|
$ 535,029
|
$ 604,618
|
$ 419,470
|
$ 425,374
|
X |
- DefinitionAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AdditionalPaidInCapitalCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
+ Details
Name: |
us-gaap_MinorityInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 23 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 105 -SubTopic 10 -Section 65 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 105 -SubTopic 10 -Section 65 -Paragraph 6 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (e)(3) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 5 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(2) -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 848 -SubTopic 10 -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 17 -URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(3) -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(2) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(1) -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(1) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
Sale of Cullinan Pearl and Co-Development Agreement with Taiho - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended |
3 Months Ended |
6 Months Ended |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
|
|
Repayment of convertible notes |
|
|
|
$ 0
|
$ 2,200
|
net of cash transferred |
|
|
|
2,898
|
|
Gain on sale of Cullinan Pearl |
|
$ 0
|
$ (276,785)
|
0
|
(276,785)
|
Payment held in escrow |
|
|
|
5,000
|
|
Research and development |
|
27,391
|
26,411
|
79,487
|
50,947
|
Prepaid expenses and other current assets |
|
619
|
|
619
|
|
Pearl - Taiho |
|
|
|
|
|
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
|
|
Repayment of convertible notes |
|
|
|
|
2,200
|
net of cash transferred |
$ 2,900
|
|
|
|
|
Additional receive payments from the party |
130,000
|
|
|
|
|
Receive upfront payment from party |
275,000
|
|
|
|
|
Gain on sale of Cullinan Pearl |
|
|
$ (276,800)
|
|
$ (276,800)
|
Payment held in escrow |
$ 5,000
|
|
|
|
|
Percentage of profits from potential sales |
50.00%
|
|
|
|
|
Research and development |
|
2,100
|
|
3,100
|
|
Research and development expense related to share of costs |
|
$ 5,500
|
|
$ 10,200
|
|
X |
- DefinitionAdditional receive payments from the party
+ References
+ Details
Name: |
cgem_AdditionalReceivePaymentsFromTheParty |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCash transferred with sale.
+ References
+ Details
Name: |
cgem_CashTransferredWithSale |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionGain( Loss) On Disposition Of Non Financial Assets.
+ References
+ Details
Name: |
cgem_GainLossOnDispositionOfNonFinancialAssets |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPercentage of profits from potential sales.
+ References
+ Details
Name: |
cgem_PercentageOfProfitsFromPotentialSales |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionReceive upfront payment from party
+ References
+ Details
Name: |
cgem_ReceiveUpfrontPaymentFromParty |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DefinedBenefitPlanDisclosureLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585
+ Details
Name: |
us-gaap_RepaymentsOfConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
Sale of Cullinan Pearl and Co-Development Agreement with Taiho - Schedule of cash consideration received (Details) $ in Thousands |
6 Months Ended |
Jun. 30, 2023
USD ($)
|
Book Value of Asset Sold [Abstract] |
|
Cash |
$ 2,898
|
Prepaid expenses and other current assets |
619
|
Amounts attributable to assets sold |
3,517
|
Book Value Of Liability Sold [Abstract] |
|
Accrued expenses and other current liabilities |
2,404
|
Amounts attributable to liabilities sold |
2,404
|
Total identifiable net assets sold |
1,113
|
Upfront consideration, inclusive of escrow of $5,000 and cash transferred of $2,898 |
277,898
|
Gain on sale of Cullinan Pearl |
$ 276,785
|
X |
- DefinitionAmounts Attributable to Assets Sold
+ References
+ Details
Name: |
cgem_AmountsAttributableToAssetsSold |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmounts Attributable To Liabilities Sold
+ References
+ Details
Name: |
cgem_AmountsAttributableToLiabilitiesSold |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionBook Value of Asset Sold.
+ References
+ Details
Name: |
cgem_BookValueOfAssetSoldAbstract |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBook Value Of Liability Sold.
+ References
+ Details
Name: |
cgem_BookValueOfLiabilitySoldAbstract |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGain (Loss) On Sale Of Cullinan Pearl
+ References
+ Details
Name: |
cgem_GainLossOnSaleOfCullinanPearl |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIdentifiable Net Assets Sold
+ References
+ Details
Name: |
cgem_IdentifiableNetAssetsSold |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 45 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 45 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCumulative amount of cash and other consideration received by subsidiary or equity method investee in exchange for shares or stock issued or sold. Include amounts of cash received, fair value of non-cash assets received, fair value of liabilities assumed, and fair value of any other forms of consideration.
+ References
+ Details
Name: |
us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionUpfront Consideration, Cash Transferred
+ References
+ Details
Name: |
cgem_UpfrontConsiderationCashTransferred |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AvailableForSaleSecuritiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Financial Instruments - Schedule of Short-term and Long-term Investment Marketable Securities by Security Type (Details) - USD ($) $ in Thousands |
Jun. 30, 2023 |
Dec. 31, 2022 |
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
$ 370,220
|
$ 394,623
|
Gross Unrealized Gains |
3
|
32
|
Gross Unrealized Losses |
(1,628)
|
(2,633)
|
Estimated Fair Value |
368,595
|
392,022
|
Long Term Investment |
|
|
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
18,758
|
81,436
|
Gross Unrealized Gains |
0
|
18
|
Gross Unrealized Losses |
(127)
|
(572)
|
Estimated Fair Value |
18,631
|
80,882
|
Long Term Investment | Corporate Note Securities |
|
|
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
18,758
|
81,436
|
Gross Unrealized Gains |
0
|
18
|
Gross Unrealized Losses |
(127)
|
(572)
|
Estimated Fair Value |
18,631
|
80,882
|
Short Term Investments |
|
|
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
351,462
|
313,187
|
Gross Unrealized Gains |
3
|
14
|
Gross Unrealized Losses |
(1,501)
|
(2,061)
|
Estimated Fair Value |
349,964
|
311,140
|
Short Term Investments | U.S. Government Notes |
|
|
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
74,708
|
34,029
|
Gross Unrealized Gains |
3
|
0
|
Gross Unrealized Losses |
(86)
|
(290)
|
Estimated Fair Value |
74,625
|
33,739
|
Short Term Investments | Asset-backed Securities |
|
|
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
74,434
|
16,625
|
Gross Unrealized Gains |
0
|
0
|
Gross Unrealized Losses |
(302)
|
(15)
|
Estimated Fair Value |
74,132
|
16,610
|
Short Term Investments | Commercial Paper |
|
|
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
|
18,035
|
Gross Unrealized Gains |
|
3
|
Gross Unrealized Losses |
|
(13)
|
Estimated Fair Value |
|
18,025
|
Short Term Investments | Corporate Note Securities |
|
|
Available For Sale Securities Fair Value To Amortized Cost Basis [Line Items] |
|
|
Amortized Cost |
202,320
|
244,498
|
Gross Unrealized Gains |
0
|
11
|
Gross Unrealized Losses |
(1,113)
|
(1,743)
|
Estimated Fair Value |
$ 201,207
|
$ 242,766
|
X |
- DefinitionAvailable for sale securities fair value to amortized cost basis.
+ References
+ Details
Name: |
cgem_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisLineItems |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details
Name: |
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details
Name: |
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 30 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454
+ Details
Name: |
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 30 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details
Name: |
us-gaap_AvailableForSaleSecuritiesDebtSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=cgem_LongTermInvestmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=cgem_ShortTermInvestmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
Financial Instruments - Summary of Fair Value of Financial Assets Measured on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands |
Jun. 30, 2023 |
Dec. 31, 2022 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
$ 349,964
|
$ 311,140
|
Total long-term investments |
18,631
|
80,882
|
Assets Fair Value Disclosure, Total |
368,595
|
392,022
|
Level 1 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
0
|
0
|
Total long-term investments |
0
|
0
|
Assets Fair Value Disclosure, Total |
0
|
0
|
Level 2 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
349,964
|
311,140
|
Total long-term investments |
18,631
|
80,882
|
Assets Fair Value Disclosure, Total |
368,595
|
392,022
|
Level 3 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
0
|
0
|
Total long-term investments |
0
|
0
|
Assets Fair Value Disclosure, Total |
0
|
0
|
U.S. Government Notes |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
74,625
|
33,739
|
U.S. Government Notes | Level 1 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
0
|
U.S. Government Notes | Level 2 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
74,625
|
33,739
|
U.S. Government Notes | Level 3 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
0
|
0
|
Asset-backed Securities |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
16,610
|
Total long-term investments |
74,132
|
|
Asset-backed Securities | Level 1 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
0
|
Total long-term investments |
0
|
|
Asset-backed Securities | Level 2 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
16,610
|
Total long-term investments |
74,132
|
|
Asset-backed Securities | Level 3 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
0
|
Total long-term investments |
0
|
|
Commercial Paper |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
18,025
|
Commercial Paper | Level 1 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
0
|
Commercial Paper | Level 2 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
18,025
|
Commercial Paper | Level 3 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
|
0
|
Corporate Note Securities |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
18,631
|
242,766
|
Total long-term investments |
201,207
|
80,882
|
Corporate Note Securities | Level 1 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
0
|
0
|
Total long-term investments |
0
|
0
|
Corporate Note Securities | Level 2 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
18,631
|
242,766
|
Total long-term investments |
201,207
|
80,882
|
Corporate Note Securities | Level 3 |
|
|
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] |
|
|
Total short-term investments |
0
|
0
|
Total long-term investments |
$ 0
|
$ 0
|
X |
- DefinitionLong term investments fair value disclosure.
+ References
+ Details
Name: |
cgem_LongTermInvestmentsFairValueDisclosure |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionShort term investments fair value disclosure.
+ References
+ Details
Name: |
cgem_ShortTermInvestmentsFairValueDisclosure |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details
Name: |
us-gaap_AssetsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands |
Jun. 30, 2023 |
Dec. 31, 2022 |
Accounts Payable and Accrued Liabilities, Current [Abstract] |
|
|
Accrued research and development expenses |
$ 6,130
|
$ 7,486
|
Due to Taiho under collaboration agreement, net |
3,378
|
0
|
Accrued bonus |
3,108
|
4,516
|
Convertible note and accrued interest |
1,885
|
178
|
Other current liabilities |
1,030
|
1,955
|
Total accrued expenses and other current liabilities |
$ 15,531
|
$ 14,135
|
X |
- DefinitionAccrued convertible note and accrued interest.
+ References
+ Details
Name: |
cgem_AccruedConvertibleNoteAndAccruedInterest |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAccrued expenses and other current liabilities.
+ References
+ Details
Name: |
cgem_AccruedExpensesAndOtherCurrentLiabilities |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAccrued research and development costs.
+ References
+ Details
Name: |
cgem_AccruedResearchAndDevelopmentCosts |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDue to Taiho under collaboration agreement, net
+ References
+ Details
Name: |
cgem_DueToTaihoUnderCollaborationAgreementNet |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccruedBonusesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended |
3 Months Ended |
6 Months Ended |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Accrued expenses and other current liabilities |
|
$ 2,404
|
|
$ 2,404
|
|
Research and development costs |
|
27,391
|
$ 26,411
|
79,487
|
$ 50,947
|
Harbour License Agreement [Member] |
|
|
|
|
|
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Upfront license fee |
|
|
|
25,000
|
|
Harbour BioMed US Inc. [Member] | Harbour License Agreement [Member] |
|
|
|
|
|
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Upfront license fee |
|
|
|
25,000
|
|
Harbour BioMed US Inc. [Member] | Maximum | Harbour License Agreement [Member] | Achievement Based [Member] |
|
|
|
|
|
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Aggregate amount of milestone payment |
|
|
|
148,000
|
|
Harbour BioMed US Inc. [Member] | Maximum | Harbour License Agreement [Member] | Sales Based [Member] |
|
|
|
|
|
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Aggregate amount of milestone payment |
|
|
|
415,000
|
|
Pearl - Taiho |
|
|
|
|
|
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Percentage of profits from potential sales |
50.00%
|
|
|
|
|
Research and development expense related to share of costs |
|
5,500
|
|
10,200
|
|
Accrued expenses and other current liabilities |
|
3,400
|
|
3,400
|
|
Research and development costs |
|
$ 2,100
|
|
3,100
|
|
Adimab |
|
|
|
|
|
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Research and development costs |
|
|
|
|
500
|
MIT |
|
|
|
|
|
License And Collaboration Agreements [Line Items] |
|
|
|
|
|
Research and development costs |
|
|
$ 200
|
$ 200
|
$ 200
|
X |
- DefinitionLicense and collaboration agreements.
+ References
+ Details
Name: |
cgem_LicenseAndCollaborationAgreementsLineItems |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage of profits from potential sales.
+ References
+ Details
Name: |
cgem_PercentageOfProfitsFromPotentialSales |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=cgem_HarbourLicenseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
cgem_MilestonesParameterAxis=cgem_AchievementBasedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
cgem_MilestonesParameterAxis=cgem_SalesBasedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
Stockholders' Equity - Additional Information (Details) - USD ($)
|
3 Months Ended |
6 Months Ended |
|
|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jan. 31, 2023 |
Dec. 31, 2022 |
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Dividends declared |
$ 0
|
|
$ 0
|
|
|
|
Common stock, voting rights |
|
|
Each share of common stock entitles the holder to one vote and to receive dividends when and if declared by the board of directors of the Company.
|
|
|
|
Preferred Stock, Par or Stated Value Per Share |
$ 0.0001
|
|
$ 0.0001
|
|
|
$ 0.0001
|
Number of shares of common stock, percentage |
9.99%
|
|
9.99%
|
|
|
|
Increase in number of shares of preferred stock, percentage |
19.99%
|
|
19.99%
|
|
|
|
Shares issued |
647,500
|
|
647,500
|
|
|
0
|
Shares sold/issued |
42,735,304
|
|
42,735,304
|
|
|
45,796,449
|
Losses attributed to noncontrolling interests |
$ (0)
|
$ (833,000)
|
$ (179,000)
|
$ (1,627,000)
|
|
|
Biotechnology Value Fund, L.P exchange agreement [Member] |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Newly designated Series A preferred stock |
|
|
|
|
600,000
|
|
Preferred Stock, Par or Stated Value Per Share |
|
|
|
|
$ 0.0001
|
|
Number of common stock exchange |
|
|
|
|
6,500,000
|
|
In May 2023 |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Offer and sell companys common stock |
$ 125,000,000.0
|
|
$ 125,000,000.0
|
|
|
|
Common Stock |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Additional shares issued |
3,310,000
|
|
|
|
|
|
At-the-Market Equity Offering Program | In May 2023 |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Net proceeds |
$ 38,400,000
|
|
|
|
|
|
Shares sold/issued |
3,300,000
|
|
3,300,000
|
|
|
|
Treasury Stock, Common, Shares |
85,600,000
|
|
85,600,000
|
|
|
|
Cullinan Amber Corp |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Losses attributed to noncontrolling interests |
$ 0
|
100,000
|
$ 0
|
100,000
|
|
|
Cullinan Amber Corp | Series A Preferred Stock |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Percentage of share purchased as part of asset acquisition |
|
|
94.00%
|
|
|
|
Ownership interest percentage |
|
|
6.00%
|
|
|
|
Cullinan Florentine Corp | Series A Preferred Stock |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Percentage of share purchased as part of asset acquisition |
|
|
96.00%
|
|
|
|
Ownership interest percentage |
|
|
4.00%
|
|
|
|
MICA | HLBV |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Losses attributed to noncontrolling interests |
$ 0
|
700,000
|
$ 200,000
|
1,100,000
|
|
|
MICA | Series A Preferred Stock |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Percentage of share purchased as part of asset acquisition |
|
|
96.00%
|
|
|
|
Cullinan Pearl Corp | HLBV |
|
|
|
|
|
|
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items] |
|
|
|
|
|
|
Losses attributed to noncontrolling interests |
|
$ 0
|
|
$ 300,000
|
|
|
X |
- DefinitionLine Items represent common stock and Noncontrolling Interest in subsidiaries.
+ References
+ Details
Name: |
cgem_CommonStockAndNoncontrollingInterestInSubsidiariesLineItems |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIncrease in number of shares of preferred stock, percentage
+ References
+ Details
Name: |
cgem_IncreaseInNumberOfSharesOfPreferredStockPercentage |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of common stock exchange
+ References
+ Details
Name: |
cgem_NumberOfCommonStockExchange |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock, percentage
+ References
+ Details
Name: |
cgem_NumberOfSharesOfCommonStockPercentage |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPercentage of share purchased as part of asset acquisition
+ References
+ Details
Name: |
cgem_PercentageOfSharePurchasedAsPartOfAssetAcquisition |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644
+ Details
Name: |
us-gaap_CommonStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued for each share of convertible preferred stock that is converted.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644
+ Details
Name: |
us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(5)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
+ Details
Name: |
us-gaap_DividendsPayableCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe total fair value for all investments, comprising or included in the major category, of those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments) for which the entity has intentions to sell or liquidate, but the specific assets for sale or liquidation have not been identified (for example, the entity intends to sell $10,000,000 of its investments in private equity funds, but the individual investments to be sold have not been identified).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 6A -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258
+ Details
Name: |
us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(2) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
+ Details
Name: |
us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceInitialPublicOffering |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details
Name: |
us-gaap_TreasuryStockCommonShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPercentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685
+ Details
Name: |
us-gaap_VariableInterestEntityOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=cgem_BiotechnologyValueFundLPExchangeAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=cgem_MayThirtyOneTwoThousendThirtyThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cgem_CullinanAmberCorpMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cgem_CullinanFlorentineCorpMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cgem_CullinanMICACorpMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=cgem_HypotheticalLiquidationAtBookValueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cgem_CullinanPearlCorpMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
Equity-Based Compensation - Schedule of Equity-based Compensation Expense Categories In Consolidated Statements of Operations and Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] |
|
|
|
|
Total equity-based compensation |
$ 7,920
|
$ 8,608
|
$ 15,179
|
$ 15,173
|
Research and Development |
|
|
|
|
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] |
|
|
|
|
Total equity-based compensation |
3,249
|
4,379
|
6,303
|
7,039
|
General and Administrative |
|
|
|
|
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] |
|
|
|
|
Total equity-based compensation |
$ 4,671
|
$ 4,229
|
$ 8,876
|
$ 8,134
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
X |
- References
+ Details
Name: |
us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details
Name: |
us-gaap_RoyaltyExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
v3.23.2
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_LossContingenciesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
Leases - Additional Information (Details) $ in Millions |
1 Months Ended |
3 Months Ended |
6 Months Ended |
Aug. 31, 2022
ft²
|
Dec. 31, 2017
ft²
|
Jun. 30, 2023
USD ($)
|
Mar. 31, 2022
USD ($)
|
Jun. 30, 2023
USD ($)
|
Jun. 30, 2022
USD ($)
|
Lessee Lease Description [Line Items] |
|
|
|
|
|
|
Operating Lease expense |
|
|
$ 0.4
|
$ 0.1
|
$ 0.9
|
$ 0.3
|
Sublease income |
|
|
$ 0.1
|
|
$ 0.3
|
|
Operating lease commence date |
|
Feb. 01, 2018
|
|
|
|
|
Operating lease expiration date |
|
|
|
|
Jun. 30, 2024
|
|
Massachusetts |
|
|
|
|
|
|
Lessee Lease Description [Line Items] |
|
|
|
|
|
|
Operating lease rentable area | ft² |
14,000
|
8,000
|
|
|
|
|
X |
- DefinitionOperating lease commence date.
+ References
+ Details
Name: |
cgem_OperatingLeaseCommenceDate |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionOperating lease rentable area.
+ References
+ Details
Name: |
cgem_OperatingLeaseRentableArea |
Namespace Prefix: |
cgem_ |
Data Type: |
dtr-types:areaItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format.
+ References
+ Details
Name: |
us-gaap_LeaseExpirationDate1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_LesseeLeaseDescriptionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating lease expense. Excludes sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 4 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977
+ Details
Name: |
us-gaap_OperatingLeaseExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of sublease income excluding finance and operating lease expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details
Name: |
us-gaap_SubleaseIncome |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=country_MA |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
X |
- DefinitionOperating Lease Payments Proceeds
+ References
+ Details
Name: |
cgem_OperatingLeasePaymentsProceeds |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(2) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
+ Details
Name: |
us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(4) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(3) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.23.2
Net Income (Loss) per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Numerator: |
|
|
|
|
Net loss attributable to common stockholders of Cullinan |
$ (32,214)
|
$ 174,898
|
$ (90,176)
|
$ 162,800
|
Denominator |
|
|
|
|
Weighted-average common stock outstanding - basic |
39,952
|
44,873
|
40,315
|
44,654
|
Dilutive effect of common stock issuable from assumed exercise of equity awards |
0
|
1,508
|
0
|
1,735
|
Weighted-average common stock outstanding - diluted |
39,952
|
46,381
|
40,315
|
46,389
|
Net income (loss) per share: |
|
|
|
|
Basic |
$ (0.82)
|
$ 3.90
|
$ (2.24)
|
$ 3.65
|
Diluted |
$ (0.82)
|
$ 3.77
|
$ (2.24)
|
$ 3.51
|
X |
- DefinitionDilutive effect of common stock issuable from assumed exercise of equity awards
+ References
+ Details
Name: |
cgem_DilutiveEffectOfCommonStockIssuableFromAssumedExerciseOfEquityAwards |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEarnings net loss per share
+ References
+ Details
Name: |
cgem_EarningsNetLossPerShare |
Namespace Prefix: |
cgem_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (e)(4) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 9: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (e)(4) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 25: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetIncomeLossAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Apr 2024 to May 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From May 2023 to May 2024